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The thesis research consists of two projects: the major focus is using population approach to 
account for the systemic availability variability of Mycophenolate Mofetil (MMF) in human and 
providing insights into developing a predictive bioequivalence (BE) test. A separate small project 
on text mining via natural language processing (NLP) is included for drug Biopharmaceutics 
Classification System (BCS) classification. 
 
The prodrug MMF, which is pre-systemically hydrolyzed into the pharmacologically active 
compound Mycophenolic Acid (MPA), has been widely used for the prophylaxis of acute allograft 
rejection in solid organ transplantation. However, the huge variability in plasma level makes MMF 
development difficult due to the great challenge of meeting the traditional BE limits. Numerous 
models have been developed in the past decade to explain the variability with the emphasis on 
characterizing the enterohepatic circulation (EHC), while the variability arising from absorption, 
can also contribute to the remarkable MPA variability to a great extent, but has been ignored for 
this BCS class 2 drug. 
 
Two population pharmacokinetics (PK) models of MMF focusing on the absorption process were 
developed based on the plasma concentrations of MPA and its major metabolite MPAG in a long-
term MMF treatment on liver transplant patients. The MPA PK profiles were best characterized 
by a two-compartment disposition model with zero inter-individual variability (IIV) of elimination 
 xi 
(K20), lag time (Tlag) but considerable inter-occasion variability (IOV) regarding systemic 
appearance rate (Ka), K20 and volume of distribution (V2). The second model took into 
consideration the EHC by including MPAG profiles as well. The results from both models 
showcased that the within-subject variability (WSV) of the MMF’s systemic appearance played a 
much more significant role than the IIV. The large WSV can be mechanistically explained by the 
gastrointestinal (GI) physiological dynamics, especially gastric emptying (GE) in the fasted state 
regulated by migrating motor complex (MMC) and in the fed state by the caloric content with 
irregular patterns of GI motility and secretion. The results implied that dosing under fed conditions 
was recommended for the in vivo clinical BE study of MMF to reduce the WSV and that 
developing a predictive in vitro dissolution test with sufficient simulation of the GI physiological 
dynamics would be a good surrogate. 
 
The second project explored the application of NLP in drug BCS classification. NLP, a confluency 
of artificial intelligence and computational linguistics, has gained widespread popularity in tech 
companies for machine translation, chatbot system, etc. In biotech and pharmaceutical industry, 
NLP-based text mining has been utilized to transform text information for decision support in 
multiple areas, including gene disease mapping, biomarker discovery, drug-drug interaction, and 
pharmacovigilance. 
 
The BCS system, designed to recommend a waiver of in vivo bioavailability and BE studies for 
immediate-release (IR) solid oral drug products, classifies drugs based on their aqueous solubility 
under physiological pHs and intestinal permeability. However, there’s no complete summarization 
of drug BCS classification information published to date. This project extracted solubility, 
 xii 
permeability and/or BCS class information of IR solid oral dosage forms in the human GI tract or 
simulated in vitro experiments from the FDA orange book, drug labels, FDA review documents, 
along with some selected literatures, and identified drug BCS class via NLP technology. The text 
mining results can be one of the key components in building up a database containing drug oral 







Chapter 1 Physiological Dynamics in Upper Gastrointestinal Tract 




As the most prevalent drug delivery route, the upsides of oral dosing include easy administration, 
good patient compliance, and low manufacturing cost. However, one of biggest hurdles of 
developing an oral dosage form is the complexity of oral absorption process, which depends on GI 
tract environment under inter-digestive and/or post-prandial conditions, the physicochemical 
properties of the drug and the properties of dosage forms1,2. 
 
BCS was developed to aid in understanding and predicting drug oral absorption in the GI tract and 
has been endorsed by the regulatory agencies worldwide and the ICH for quality control in 
manufacture and marketing, as well as biowaiver of in vivo BE studies for IR dosage forms3,4. In 
this system, drug substances are classified into four classes on basis of their aqueous solubility in 
the GI physiological pH range (pH: 1.0-6.8) and their intestinal permeability (typically jejunal 
mucosal membrane):  
• Class 1: high solubility, high permeability;  
• Class 2: low solubility, high permeability;  
• Class 3: high solubility, low permeability;  
• Class 4: low solubility, high solubility5.  
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According to U.S. FDA guidance, a drug substance is considered “highly soluble” when the highest 
strength is soluble in 250 mL or less of aqueous media within the pH range of 1-6.8 at 37±1°C, 
and “high permeable” when the systemic bioavailability or the extent of absorption in humans is 
determined to be 85 percent or more of an administered dose based on a mass balance 
determination (along with evidence showing stability of the drug in the GI tract) or in comparison 
to an intravenous reference dose. The definition of a high permeability drug was derived from a 
landmark publication of human jejunal permeability and the fraction drug absorbed5. A drug 
product is “rapidly dissolving” when a mean of 85 percent or more of the labeled amount of the 
drug substance dissolves within 30 minutes, using United States Pharmacopeia (USP) Apparatus 
1 at 100 rpm or Apparatus 2 at 50 rpm (or at 75 rpm when appropriately justified in a volume of 
500 mL or less (or 900 mL when appropriately justified) in each of the following media: (1) 0.1 N 
HCl or Simulated Gastric Fluid USP without enzymes; (2) a pH 4.5 buffer; and (3) a pH 6.8 buffer 
or Simulated Intestinal Fluid USP without enzymes3. 
 
The physiological dynamics in the upper GI tract (stomach, duodenum, and proximal jejunum) in 
different states (fasted or fed) is presumably to be the major source of variabilities in the dissolution 
and subsequent systemic availability (“absorption”) profiles of drug products with active 
pharmaceutical ingredient (API) particularly having low solubility in the GI tract, especially BCS 
class 2 drugs6. In virtually all the cases, dissolution in the GI fluid milieu is a prerequisite for 
molecular drug absorption following oral administration. For BCS class 2 drugs, the dissolution 
process inevitably introduces considerable variability due to the vulnerability of the drug product 
to the environmental changes at absorptive sites, making it a determining factor in drug oral uptake 
and systemic appearance. The great variability observed in the systemic appearance of BCS class 
2 orally dosed drugs is considered as one of the top concerns in the design of BE studies and also 
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in optimizing therapeutic drug monitoring (TDM). Therefore, a mechanistic characterization of 
the variability with regard to systemic appearance for this type of drug products from the 
perspective of dissolution regulated by GI physiological dynamics and a further application of this 
knowledge to the prediction of drug oral absorption process would be beneficial for BCS class 2 
drug development and clinical efficacy and safety. Because of the high permeability nature, most 
of BCS class 2 drugs are absorbed in the duodenum and proximal jejunum after being emptied 
from stomach and dissolved in the GI fluid. This chapter is focused on reviewing the current 
studies regarding physiological dynamics in the upper GI tract and its relationship to drug oral 
absorption models in healthy adult humans. 
 
1.2 Physiology of upper GI tract and organs draining to it 
Before delving deep into the physiological dynamics affecting BCS class 2 drug oral uptake, it is 
necessary to discuss the upper GI tract under normal circumstances, so this section will center on 
the physiology of stomach, duodenum, jejunum, the pancreas and biliary system most relevant to 
drug oral absorption, as well as the underlying physiological basis. 
 
1.2.1 Functional anatomy 
1.2.1.1 Stomach 
As the organ that initiates the absorption process in the gut, the stomach (Figure 1.1A) 
accommodates the ingesta upon its arrival in the fundus, gradually transfer the ingesta to the body 
and antrum, mixes it with gastric secretions, breaks it down to small-sized particles, and finally 
empty the luminal contents at a rate that allows efficient digestion and absorption in the more distal 
segments of the small intestine. 
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Functionally, the stomach can be divided into the proximal gastric reservoir and the distal gastric 
pump for considerations of motility7 with the sphincter pylorus (antral musculature) at the 
gastroduodenal junction. The proximal stomach, consisting of the fundus, and proximal portion of 
the body, serves primarily as a reservoir and to move gastric contents to the distal stomach8,9. The 
gastric pump, including the distal portion of the body and the antrum, serves predominantly to 
grind and triturate ingesta and empty the stomach9,10. In addition, the pylorus is a narrow opening 
with folded, redundant mucosa. The periodic contractions generated at pylorus support for 
intermittent contractions. These properties enable it to control the amount and size (< 1 mm) of 
ingesta that can exit the stomach, making it a mechanical barrier and sieve. Conversely, when the 
pylorus opens and allows passage of luminal content to distend the duodenum, duodenal motor 
activity is stimulated8-10. Because the pylorus is an electric isolator and there exist different 
pacemakers in the stomach and duodenum, distinct frequencies between antral and duodenal 
contractions are observed. It is termed Antro-pyloro-duodenal coordination. In this coordination, 
the duodenum can contract three to four times during an antral wave. The contractions of the 
proximal duodenum cease during the phases of gastric emptying.9 
 
The stomach can also be divided into two functional regions based on its secretory function: the 
oxyntic gland area and the pyloric gland area, respectively11,12. The oxyntic (oxys, Greek for acid) 
area, including the fundus and body of the stomach, contains approximately 75% of the gastric 
glands, so-called oxyntic glands. The characteristic secretions of the stomach are produced by 
specialized cell types in these glands. The most significant secretory product of the stomach, in 
the regard of drug oral absorption, is gastric acid (HCl). The stomach secretes around 400 mmol 
HCl per day, almost all of which enters the duodenum via gastric emptying13, making it one of the 
crucial components of duodenal fluid. The concentration of H+ reflected in the pH is typically 1-2 
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in the fasted state (0.01-0.1 M)14. The antrum of the stomach gains its name for being immediately 
proximal to the pylorus, contains glands that secrete gastrin, the primary regulator of post-prandial 
gastric secretion. 
 
1.2.1.2 Duodenal cluster unit 
Together with the pancreas and biliary system, the duodenum makes up the duodenal cluster unit. 
This segment of the gastrointestinal system plays a critical role in the regulation of digestion and 
absorption10. Figure1.1B depicts the overall anatomy of duodenum and its relevant organs. 
 
Pancreas 
The exocrine pancreas is the primary source of enzymes for digestion and bicarbonate for the GI 
predominant buffer. As alluded to above, large volume of strong acid HCl secreted by the stomach 
enters the duodenum with gastric emptying, placing the duodenal mucosa at risk for irreversible 
cellular acidification. In response to this acid onslaught, the duodenal cluster unit secretes 
bicarbonate to neutralize the HCl in the duodenal lumen. Quantitatively, the pancreas plays the 
major role among all the organs of the duodenal cluster unit in supplying the bicarbonate necessary 
to neutralize gastric10. 
 
The secretion of pancreatic bicarbonate is regulated by the secretin from the S cells in the duodenal 
mucosa. The S cells can be considered to act functionally as pH meters, sensing the acidity of the 
luminal contents (Figure 1.2). As the pH falls, due to the entry of gastric acid, secretin is released 
from the S cells and travels through the bloodstream to bind to receptors on pancreatic duct cells, 
as well as on epithelial cells lining the bile ducts and the duodenum itself. These cells, in turn, are 
evoked to secrete bicarbonate into the duodenal lumen, thus causing a rise in pH that will 
eventually shut off secretin release. The pancreas is quantitatively the most important in the 
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bicarbonate secretory response, although the ability of duodenal epithelial cells to secrete 
bicarbonate may be critically important to protect them from gastric acid, especially in the first 
part of the duodenum, which is proximal to the site of entry of the pancreatic juice and bile. The 
threshold for secretin release appears to be a luminal pH of less than 4.5.10 
 
Biliary system 
The biliary system, consisting of biliary tract and gallbladder, is responsible for transporting bile 
out of the liver into the GI lumen. The secretory products released by the biliary system include 
bile acids, phospholipids, cholesterol, bilirubin, and bicarbonate. Among them bile acids aid in 
drug solubility and dissolution by forming mixed micelles, when above their critical micelle 
concentration (CMC).10 Biliary secretions mix with those coming from the pancreas at the 
common bile duct, and flow into the duodenal lumen in a controlled fashion when the sphincter 
relaxes in response to neurohumoral influences.10 
 
Duodenum 
The absorptive capacity of the small intestine (Figure 1.1C) is remarkably amplified attributed to 
its massively amplified surface area compared to that of stomach. As we know, the intestine is not 
a simple cylinder, but instead is amplified first by folds in the mucosa, then by the presence of 
crypts and villi, and finally by the presence of abundant microvilli on the apical poles of individual 
epithelial cells, increasing the overall surface area by a factor of 600-fold. This amplification of 
the surface area makes it the perfect place in the gut to handle luminal contents including drugs 
and nutrients. 
 
The first segment of the small intestine, approximately 12 inch in length, is referred to as the 
duodenum, and begins as a bulb-shaped structure immediately distal to the pylorus. The motor 
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function of duodenum is to mix ingesta with GI secretions so that the luminal contents can be 
absorbed or propel ingesta relatively quickly so that it does not act as an obstruction to further 
gastric emptying. Duodenal mucosa also contributes to the secretion of bicarbonate, but its role is 
minor compared to pancreatic ductular cells.10 
 
1.2.1.3 Jejunum 
The jejunum serves as main absorptive site for most of nutrients and drugs in the healthy individual 
and has a markedly amplified surface area due to the presence of surface folds, tall and slender 
villi, and microvilli mentioned above. This increase in surface area, combined with cyclical 
discontinuous contractions caused by GI motility patterns (summarized in 1.2.2.1), lead to rapid 
absorption of nutrients and highly permeable drugs. 
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Figure 1.1 The overall anatomy of the stomach (A) 15, duodenal cluster unit (B) 16 and small intestine (C) 17. 
 
Figure 1.2 Regulation of duodenal pH by pancreatic bicarbonate secretion in response to gastric acid emptying. 
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1.2.2 Physiological basis 
1.2.2.1 Motility 
The mixing and propulsive motor functions of the gut to facilitate absorption are primarily 
governed by cyclical phasic contractions. The rate of propulsion generally slows distally in the 
small intestine, while mixing intensifies18. 
 
In the inter-digestive state, phasic contractions become organized as a cyclical motor pattern 
migrating motor complex (MMC) typically initiated in the stomach or duodenum. This contractile 
activity consists of:  
• Phase 1 activity that has little or no contractile activity;  
• Phase 2 activity that shows an increasing number of intermittent but irregular and rarely 
propulsive contractions;  
• Phase 3 activity that is a group of the largest amplitude peristaltic waves occurring at their 
maximum frequency, and the entire group of contractions migrates distally over a long 
distance, usually the entire small intestine, in an organized fashion (Figure 1.3)8-10,19. In the 
absence of feeding, MMC cycle lasts around 100 mins: the quiescent phase 1 comprises 
40-60% of the cycle, phase 2 comprises 20-30% of the overall cycle, and the phase 3 
involves a 5-10 min burst of intense phasic contractions. The onset of phase 3 is correlated 
with plasma motilin level10. It is noteworthy that the pylorus opens fully in the phase 3 of 
MMC and the actual propulsion of luminal contents is caused by the propagating phasic 
contractions within phase 3 activity. As the contractile activity propagates it becomes less 





Figure 1.3 The three phases of MMC in the fasted state recorded using a stationary water-perfused catheter system at gastric antrum 
(G) and the first and second parts of the duodenum (D1 and D2, respectively). 
 
Following ingestion of a meal or any type of nutrients, there is an immediate change in the 
contractile pattern of the stomach and small intestine to the fed pattern. The pylorus remains closed 
for prolonged periods with only intermittent openings that allow small particles (< 1-2 mm) to 
enter the duodenum. The motility fed pattern of the small intestine differs from the fasted pattern 
with variable frequency, amplitude, and propagation to enable the mixing of luminal contents and 
their subsequent aboral transport. Up to 50% of the phasic contractions in the duodenum is reported 
to actually move the luminal contents orally10.  The duration of the fed pattern of motility in the 
small intestine depends on the caloric content of the meal ingested as well as its composition19. 
 
1.2.2.2 Secretion 
Ample experimental data support a coupling between inter-digestive GI motility and secretion20-
22. The MMC also cycles in phase with contractile activity of the gallbladder and relaxation of the 
sphincter of Oddi, as well as with periodic increases in secretory function of the intestine and 
organs draining into it (Table 1.1)10. Phase 1 secretion is characterized by minimal exocrine 
pancreatic and gastric secretion, absence of bile in the duodenum, and maybe a refractory phase 
for pancreatic secretion. During phase 2 secretion increases. As the irregular motor activity 
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intensifies, exocrine pancreatic secretion into the duodenum reaches maximal inter-digestive 
secretory rates several minutes before the onset of phase 323. During phase 3, the exocrine 
pancreatic secretion decreases until the upper GI tract resumes the quiescence of phase 1. Bile acid 
secretion parallels pancreatic enzyme secretion and peaks during late phase 224. Bile entry into the 
duodenum is preceded by gallbladder contraction and emptying of around 25% of gallbladder 
contents, which accounts for most of the bile within the duodenum during phase 2. In contrast, 
peak gastric acid secretion and bicarbonate secretion into the duodenum occur slightly later 
coinciding with the start of phase 3.25 
 
Table 1.1 Secretion and absorption of the gut marked by MMC 
 Components Phase 1 Late phase 2 Early Phase 3 
Secretion 
HCl min  max 
HCO3- min  max 
Bile min max  
Pancreatic enzyme min max  
Absorption Water max min  
 
Under the post-prandial, GI secretion can generally be divided into three phases10: 
• Cephalic Phase: in response to any sight, smell, taste and even the thought of the food, the 
vagal outflow initiates gastric secretory behavior to readies the stomach to receive the meal 
and 20-25% of pancreatic secretion with high concentration of digestive enzyme; 
• Gastric Phase: in addition to vagal influences continuing from the cephalic phase, gastric 
secretion is amplified further by mechanical and chemical stimuli when the stomach 
distends to accommodate the volume of the meal. These vago-vagal reflexes also transmit 
information downstream to ready more distal segments of the intestine to receive the meal. 
The combined influence of neurocrine and endocrine signals makes this phase 
quantitatively most important for gastric secretion. At this phase, the pancreatic secretion 
is only 10% also with high concentration of enzymes; 
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• Intestinal Phase: as the meal moves out of the stomach into the duodenum, the gastric 
secretion is suppressed in response to the fall of pH in the lumen, while high volumes (60-
70%) of pancreatic juice is produced with decreased concentrations of protein. 
 
1.3 Physiological dynamics in the upper GI tract and the corresponding models 
In a typical BE study, solid orally administrated drug products like tablets or capsules are usually 
given with a glass of water (250 mL) in the normal state. We’ll see below how variable this 
“normal” GI fasted state is due to the MMC described above and further how different the fasted 
and fed state are in terms of motility and secretion physiologically. 
 
1.3.1 Gastric emptying (GE) and upper small intestinal transit variations 
The rate of GE and upper small intestinal transit is negatively associated with the extent of 
absorption: if motility is increased, hastening the transit of substances along the intestine, there 
will be less time for absorption to take place; if transit is slowed, absorption can catch up with the 
presented the volume luminal contents. 
 
1.3.1.1 Inter-digestive 
Conventionally, human gastric emptying is regarded as continuous first-order process, however, 
an increasing amount of research demonstrated the process of gastric emptying to be far from that 
simple. For liquid volumes of 240 to 800 mL, experimental measurements of gastric emptying 
half-time varied from 8 to 18 minutes26-29. In the fasted state, the gastric emptying rate of liquid 
was shown to heavily rely on MMC phases and the larger volume of 200 mL phenol red solution 
leaves the stomach with a half-life of 11.8 min, being less dependent on gastric motility than the 
smaller volume of 50 ml solution30. In the study of Mudie et al., 75% of the subjects displayed 
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first-order emptying patterns while 25% had non-first order, biphasic emptying after drinking 240 
mL water 31.  
 
Likewise, human intestinal transit is traditionally modeled with continuous first-order 
approximation. There is very limited published experimental evidence regarding intestinal transit 
in the fasted state. But according to the results of mass transport analysis of phenol red, first-order 
process is obviously inadequate to characterize duodenal and jejunal transit32. Considering the high 
frequency and incidence of MMC in the proximal intestine, MMC presumably plays a critical role 
in the complicated hydrodynamics pattern in proximal small intestine.  
 
GE and intestinal transit are more likely to occur in a discontinuous fashion inferred from 
experimental evidence and GI physiology theory. After Schiller et al. reported that that fluid in the 
fasted small intestine is not a continuous watery compartment but rather in discrete packets of 
varying volumes, Mudie et al. further quantified the volume and number of water pockets in the 
small intestine of fasted healthy humans.31,33 The resting small bowel water was distributed in 8 ± 
1 pockets of 4 ± 1 mL on average each, rose to 15 ± 1 pockets of 6 ± 2 mL each at peak time, and 
16 ± 3 pockets of 5 ± 1 mL each at 45 min before gradually returning to the baseline level. 
Regardless of water intake, the number of liquid pockets in the smaller 0.5-2.5 mL size bin was 
markedly higher than all the larger bin sizes and that there was no significant difference between 
the remaining larger bin sizes, but most of the total volume of liquid was found in the larger 
pockets. At the time point of 45 min after water administration, the smallest pockets (0.5-2.5 mL) 
account for less than 5% of the total liquid volume, the smaller pockets (2.5-20 mL) claims about 
40% of the total volume, and the largest amount of liquid (∼60% of the volume) is contained in a 
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small number of large pockets (> 20 mL)31. According to the overview of GI physiology described 
above, it’s natural to relate the discrete fluid packets emptied from the stomach with time-varying 
volumes phenomena to the varying onset, frequency, amplitude, duration, direction and distance 
of antral contraction and small intestinal peristalsis, the phasic secretion of the stomach, pancreas, 
biliary system and duodenal mucosal, and the different frequency and extent of opening of pylorus 
and Sphicter of Oddi during MMC cycle, thus making any detailed mechanistic model of this 
process extremely complex. 
 
The identification of MMC-driven discontinuous, small volume of fluid packets helps to explain 
the variability of oral absorption of BCS class 2 drug and consequently has significant implications 
for TDM and the design of BE studies of this type of drug products. To begin with, the randomness 
of the dosing time relative to MMC phases undoubtably brings in the variation of the delivery of 
drug to the absorptive site. If the drug is administrated at the beginning of MMC phase 1, then it 
will likely be kept in the stomach for a significant period of time by the pylorus; To the contrary, 
if the drug is dosed during phase 3, the strong contractile period, then it will pass the stomach 
through the fully open pylorus into the small intestine without residence. In this case, the 
absorption profiles would also be quite variable due to distinct GI motility patterns. In addition, 
the presence of the small fluid packets would contribute to the within-subject variability of drug 
Cmax and Tmax. If the volume of a fluid packet is lower than the volume needed to completely 
dissolve the drug particles it encloses, the undissolved drug will not be transported across the GI 
mucosal cells and show up in the circulating system together with the dissolved counterpart. These 
drug particles are often held back in the GI lumen until they encounter appropriate fluid packets. 
For instance, in a study of Schiller et al, only 50% of the ingested non-disintegrating capsules were 
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surrounded by fluid in the fasted small intestine33. Hence, the randomness of the timing and size 
of fluid packet drug particles are exposed to may lead to the uncertainty of the systemic appearance 
of low solubility drugs, especially the amplitude of Cmax and the timing of Tmax. Furthermore, 
the discontinuity of the fluid packet would inevitably incur higher variability than a continuous 
fluid flow system. If a drug product is completely dissolved in the stomach, it will remain there 
until the arrival of the next antral contraction; if a drug product is emptied from the stomach as the 
undissolved particles, none of them will be dissolved in quiescent period before the next wave of 
intestinal peristalsis brings fluid packets. So we speculate there are jumps in the cumulative plot 
of dissolved drug vs time. Collectively, huge intra-individual variability would be anticipated in 
the dissolution profiles and systemic appearance due to this super dynamic GI transit feature. 
CellCept, the IR solid oral dosage form of MMF, is one example of BCS class 2 under TDM. The 
major variability of its within-subject variability comes from GE, which will be discussed in detail 
in Chapter 2. The inter-individual variability of its systemic appearance will be captured by 
sufficiently simulating the GE dynamics, therefore the Cmax will be predicted more accurately in 
TDM and also help the BE study to focus on drug product difference by minimizing the 
confounding effect of GI dynamics. 
 
1.3.1.2 Post-prandial 
Food ingestion is known to profoundly alter the GI environment by interrupting the cyclical MMC. 
As discussed previously, the motor patterned of the antrum under fed conditions are featured as 
mixing and grinding, while in small intestine they are called mixing and segmentation10. With 
propulsion occurring significantly less aborally and more orally, a delayed GE and prolonged 
intestinal transit can be expected34. 
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It has been demonstrated that the caloric load and the type of nutrients ingested play a critical role 
in regulating the motor response the upper GI tract (Figure 1.4). Fed pattern durations of about 
180, 360, and 410 mins were reported to occur after meals of 630, 1260, and 2520 kJ, 
respectively35. In general, fat produces a longer fed pattern than carbohydrate or protein, but the 
timing of the meal does not appear to affect the GI transit for the same nutrient load. The GE of 
inert liquids is most rapidly, while for the liquid contains nutrients, a rapid initial phase is then 
followed by slowed exit, apparently reflecting feedback from the small intestine. Moreover, 
emptying of solids from the stomach is slower yet, with a half time of approximately 1–2 hours 
during which retropulsion and mixing take place. This lag phase is increased in duration if large 
particles are swallowed as a whole. After the lag phase, a linear phase of emptying of a particulate 
suspension occurs at a relatively constant rate, with the size of 1-2 mm and the volume of 2-3 mL. 




Figure 1.4 GE time curve of different types of gastric contents 
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Therefore, the regulatory agency like FDA published a standard for the food-effect bioavailability 
(BA) and fed BE studies. A high-fat (approximately 50 percent of total caloric content of the meal) 
and high-calorie (approximately 800 to 1000 calories) meal is recommended as a test meal for 
food-effect BA and fed BE studies. This test meal should derive approximately 150, 250, and 500-
600 calories from protein, carbohydrate, and fat, respectively. In NDAs, it is recognized that a 
sponsor can choose to conduct food-effect BA studies using meals with different combinations of 
fats, carbohydrates, and proteins for exploratory or label purposes. However, one of the meals for 
the food-effect BA studies should be the high-fat, high-calorie test meal described above. As for 
the fed treatment, following an overnight fast of at least 10 hours, subjects should start the 
recommended meal 30 minutes prior to administration of the drug product. Study subjects should 
eat this meal in 30 minutes or less; however, the drug product should be administered 30 minutes 
after start of the meal. The drug product should be administered with 240 mL (8 fluid ounces) of 
water. No food should be allowed for at least 4 hours post-dose. Water can be allowed as desired 
except for one hour before and after drug administration. Subjects should receive standardized 
meals scheduled at the same time in each period of the study.36 
 
1.3.1.3 Models 
A great many of endeavors have been made to model drug oral absorption, however, the modeling 
and simulation of BCS class 2 drug systemic appearance is still tough partly due to the variable GI 
transit. How the GI transit kinetics are incorporated in published models are included in Table 1.2. 
 
A typical empirical absorption model usually assumes a well-mixed GI lumen compartment with 
zero-order or first-order constant absorption coefficient with or without a lag time. Another 
commonly used empirical model is the one including two parallel first-order constant absorption 
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coefficient with two lag times (Model 1) to describe double peaks in the absorption phase. 
Sometimes, a simultaneous or a sequential combination of zero-order and first-order absorption is 
employed, for example the first-order followed by zero-order absorption in the case of Model 2. If 
the zero-order and/or first-order absorption assumption is still inadequately to describe the 
complicated absorption profile, Weibull function and its variants may worth a try. The idea of 
Weibull function has been used in both modeling (Model 3) and simulation in fasted (Model 4) 
and fed state (Model 5) to account for the GI motility variability. Occasionally, the Michaelis-
Menten (MM) equation can be introduced to describe the saturable absorption phenomenon 
(Model 6). The TPLAG model (Model 7) simulated the oral absorption with two first-order 
constant absorption coefficients with two lag times conceptually, to account for the dynamics in 
fluid absorption or secretion, absorption surface area, and time-varying motility caused by two 
phases of GE. More sophisticated models include the one using a sum of inverse Gaussian 
functions (Model 8) and the one appling the law of Laplace, Hooke, and Poisseuille to derive a 
nonlinear first order deterministic elimination GE model (Model 9) in fasted and fed state, 
respectively. These empirical modelings provide estimates of the population mean of absorption 
kinetics implying GI transit and the corresponding variability, which can be used as the prior 
information or reference value for the subsequent prediction model, but nothing related with the 
GI physiological mechanism. The empirical simulations, though too simple, are the exploratory 
works toward building physiologically-based absorption models. 
 
The mechanistic models handle the oral absorption from a bottom-up approach. The parameters of 
GI transit are explicitly specified in the model based on experimental data or literature search rather 
than inferred from the parameter estimation of the absorption kinetics in the empirical modelings. 
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At the early phase of developing such oral absorption simulation models, the GI transit were just 
assumed to be a zero-order or first-order process with constant transit coefficients (Model 10-12). 
A higher transit rate was applied in the fasted state and a lower transit rate in the fed state. Then 
more physiological information was introduced later, for example unlike the CAT model that 
supposes all the small intestinal compartment share the same transit coefficient, the refined ACAT 
model (Model 13) included compartment-dependent physiological parameters to represent the 
distinct features of each segment of human GI tract. Model 14 assumed first-order GE with three 
constant coefficients representing the three phases of MMC, but in the real work, the change of 
motility pattern is not a jump step. Model 15 designed another bypass compartment to 
accommodate the huge variability resulting from the dynamic GI motility patter and explored the 
potential relationship of the fraction of fluid flowing to the bypass compartment vs time to MMC 
phase 3 post-dose. Model 16 started to simulate MMC pattern directly in a non-linear way with 
the Fourier approximation for GE rate and a sigmoidal decay function for the lag time. The 
absorption profiles could also be modeled by a delayed differential equation (DDE) and a sine 
function to fit the complicated multiple peaks in the absorption phase. Interestingly, Model 17 
employed PCA to investigate the impact of GE on individual PK parameters, trying to link the 
empirical modeling work with GI physiology. Considering the complexity of developing a discrete 
model, most of the oral absorption models handle the discontinuous GI transit continuously and 
smoothly with lag time(s) from drug administration to systemic appearance, while Model 18-20 
were stochastic models designed to capture these spurts in a discrete system. Meta-model was used 
to modeling the probability of flow from one compartment to another by first-order transit in the 
fasted and fed state (Model 18). Due to the irregular pattern of pylorus opening in the fed state, the 
GE process was simulated with the power exponential function of standard Wiener process 
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representing the irregular decrements of gastric contents after a meal in Model 19. Model 20 
simulated the occurrence of GE with nonhomogeneous Poisson process and the intensity of GE in 
the form of the volume of fluid pulse packets to account for time-varying contractions during three 
MMC phases in the fasted state. Obviously, the mechanistic simulation models not only allow for 
complicated model structure, but also enable prediction of GI luminal contents and systemic 
appearance on the basis of GI physiological dynamics. More examples of how to model the impact 
of GI transit on drug oral absorption can be found in Ahmad et al’s work on a quantitative review 
and meta-models in the fasted and fed state37. 
 
Table 1.2 A summary of GI dynamic variables in published models 
No Model description Reference 
1 A population PK model (fasted): 
two parallel first-order absorption: one represents the immediate first-order absorption from stomach 
and upper intestine and the other represents the delayed first-order absorption process from the lower 
intestine 
38 
2 A population PK model  (fasted): 
First-order followed by zero-order absorption 
39 
3 A population PK model (fasted): 
Two Weibull function absorption 
40 
4 A GE simulation model (fasted): 
The sum of two Weibull models in different proportions to account for the motility variability of MMC 
41 
5 A GE simulation model (fed): 
A modified Weibull model to represent time-varying gastric retention 
42 
6 A population PK model (fasted): 
A saturable absorption model (Michaelis-Menten equation) 
43 
7 A two-phase simulation model with lag time (TPLAG, fasted): 
1) First-order absorption with time-dependent absorption coefficient, representing two phases of 
GE; 
2) Constant absorption coefficient in each of the two phases of GE; 
44 
8 A population PK model (fasted): 
A parametric deconvolution method using a sum of inverse Gaussian functions to describe the 
absorption profiles 
45 
9 A GE simulation model (fed): 
1) Applied the law of Laplace, Hooke, and Poisseuille to derive a nonlinear first order 
deterministic elimination GE model assuming the initial volume of the stomach is greater than 
300 mL; 
2) If the initial volume of the stomach is less than 300 mL, some correction is needed 
46 
10 A two-tank perfect-mixing tank simulation model: 
1) First-order absorption with constant coefficients; 
2) First-order transit with constant coefficients—assume higher Q in the fasted state and lower 
Q in the fed state; 
3) Different constant intestinal pH among different populations 
47 
11 A four-compartment simulation model: 
1) Zero-order and first-order GE with different constant coefficients with or without lag time to 
represent GE in fasted and fed state; 
2) Bile salt input as a bolus in fed state and zero in fasted state; 
48 
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3) First-order transit and absorption with constant coefficients 
12 The Compartmental Absorption and Transit (CAT)—a nine-compartment simulation model (fasted and 
fed): 
1) First order GE and intestinal transit with constant coefficients; 
2) The seven small intestinal compartments have equal transit time; 
3) First-order absorption with constant coefficients; 
49 
13 The Advanced Compartmental Absorption and Transit (ACAT)-- a 18- compartment simulation model 
(fasted and fed): 
1) First order GE and intestinal transit with constant coefficients; 
2) Include compartment-dependent physiological parameter (e.g., pH, transit rate coefficients); 
50 
14 A one-compartment simulation model (fasted): 
Three distinct constant absorption coefficients in the three phases of MMC; 
51 
15 A five-compartment simulation model: 
1) Bypass compartment to facilitate transport directly to the duodenum in the fasted state; 
2) Bypass compartment to facilitate transport directly to the antrum of the stomach in the fed 
state; 
3) First-order transit; 
4) First-order absorption and zero-order secretion in duodenum and jejunum; 
5) Negligible gastric secretion  
32 
16 A eight-compartment simulation model (fasted): 
1) Assumes GE is MMC-driven motility-dependent 
2) GE rate with a Fourier series approximation; 
3) Lag time with a sigmoidal decay function; 
52 
17 Two population PK models (fasted): 
1) The first PK model using Delay differential equations; 
2) The second PK model using a sine function; 
3) The impact of GE on PK parameters investigated by applying principle component analysis 
(PCA) to the individual parameter estimates 
53 
18 A stochastic continuous-time Markov-chain meta-model (fasted and fed): 
1) First-order transit represents the probability of flow from one compartment to another; 
2) Two-compartment stomach + five-compartment small intestine with equal transit rate 
coefficient + four-compartment colon 
54 
19 A stochastic GE simulation model (fed): 
GE with Weiner process 
55 
20 A stochastic GE with fluid packet simulation model (fasted): 
1) the occurrence of GE with nonhomogeneous Poisson process to account for time-varying 
contractions during three MMC phases; 
2) the volumetric effect in the stomach; 
3) the volume of fluid packet is a function of the current stomach volume and mean packet size 
plus some deviations 
56 
 
1.3.2 GI luminal pH fluctuations 
For an ionizable low solubility drug, the solubility and dissolution rate would be greatly influenced 
by pH fluctuations, which is prominent in the upper GI tract with low buffer capacity. It is 
important to note that the buffer capacity comes from the fluid secretion into the GI lumen rather 
than reside in the GI fluid due to the unique chemistry of HCO3- and CO2. Hence, characterization 
of the pH fluctuations would promote the prediction of the fraction of BCS class 2 drug dissolved 




In fasted state, the stomach environment ranges from pH 2 to pH 4 in healthy individuals57. As the 
conduit of random gastric emptying in a random discrete fluid packet fashion31 and motility-related 
pancreatic and biliary draining25 in the low buffer capacity setting, the proximal small intestine 
experiences the most dramatic pH fluctuation throughout the whole small intestine and tapers 
down distally. A large range of pH fluctuation (pH: 1.71-7.57) in the proximal small intestine has 
been reported in Bart et al’s work (Figure 1.5)57. For example, the duodenal pH is a dynamic 
physiological parameter ranging from 2.4 to 7.558 with considerable intra- and inter- individual 
variability (Figure 1.6)59. The non-uniform input rate of main strong acid HCl from gastric 
emptying (~17 mmol/h)60 and main weak base HCO3- (~8 mmol/h)61 from the duodenal cluster 
unit secretion, and limited buffer capacity of the bicarbonate/CO2 buffer in human small intestinal 
fluids (mean: 2.26 mM/pH, range: 0.26-6.32 mM/pH)57,62,63 could all be the culprits of pH 





Figure 1.5 Mean pH versus time profiles in fasting (n = 20) and fed state (n = 17) conditions as measured in the stomach, the 
duodenum, and the jejunum (mean + SD). Data obtained from Koenigsknecht et al.64 
 
 
Figure 1.6 Individual pH versus time in fasting human duodenal fluid for five healthy subjects 
 
1.3.2.2 Post-prandial  
As shown in Figure 1.5, after food consumption, the gastric pH transiently increases, while the pH 
levels in the duodenum and Jejunum do not fluctuate as dramatically as the gastric pH, and remain 
around pH 4 to pH 6. The pH profile along the intestinal tract is dynamic under fed conditions and 
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largely depends on several factors, including the composition of food ingested, gastric secretion, 
and bile salt concentrations.65 
 
1.3.2.3 Models 
There are not many models in terms of the luminal pH fluctuation developed to date. Among the 
different types of oral absorption models in Table 1.2, only Model 10 and Model 13 (ACAT) take 
the effect of pH fluctuation into consideration. Meta-models of the impact of GI pH on oral drug 
absorption were summarized in Ahmad et al’s work.66 
 
1.4 Conclusion and discussion 
The review revealed the relationship of GI physiological dynamics with the variability of BCS 
class 2 drug oral absorption via an overview of GI physiological knowledge and an update of 
endeavors that modelers have made so far to capture the GI dynamics, especially GI transit and 
luminal pH fluctuations. This would shed light on further accounting for high within-subject 
variability of the systemic appearance of BCS class drug 2, and provide insights into dosing 
recommendation and the design of BE studies. 
 
However, due to the complexity of oral absorption process, it may be a good idea to switch from 
the traditional parametric models to some non-parametric learning, for example, the machine 
learning (ML) and artificial intelligent (AL) algorithm. After grinded into small particles, many 
high permeable drugs are emptied from the stomach to the duodenum in a random discrete fluid 
packet31, mixed well with the GI secretion and then be absorbed at the duodenum or upper jejunum 
after the delivery of intestinal transit to the absorptive site. Modeling of the discontinuous fluid 
packet emptying and GI transit, the unstable GI secretion, GI fluid buffer capacity, and the impact 
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of the drug on local pH is never an easy task, ML/AL algorithm would potentially worth a try by 
avoiding proposing a specific model structure to handle all these complicated GI events. For 
example, dimensionality reduction could be used to help figure out where the variability of 
systemic appearance mainly comes from among all these GI events, by feeding the model with a 
pool of the BCS class 2 drug product absorption data. In addition, reinforcement learning (RL) is 
another fantastic strategy for predicting drug systemic appearance in the longitudinal PK data. 
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Chapter 2 Population Pharmacokinetics of Mycophenolate Mofetil 
in Liver Transplanted Recipients and its Implication for Developing 
a Predictive Bioequivalence Test 
 
2.1 Introduction 
Mycophenolate mofetil (MMF), initially launched into the market as CellCept® in 1995, has been 
widely used as an immunosuppressant for the prophylaxis of organ rejection after kidney, heart, 
or liver transplantation with 3367 bioequivalent drug products to date68. 
 
 
Figure 2.1 The chemical structure of MMF68. 
 
MMF has an empirical formular of C23H31NO7 with a molecular weight of 433.50. The chemical 
structure of MMF is depicted in Figure 2.1. It is slighted soluble in water (43 ug/mL at pH 7.4) 
and soluble in acidic medium (4.27 mg/mL at pH 3.6). The pKa values for MMF are 5.6 for the 
morpholino group and 8.5 for the phenolic group. MMF is classified as class 2b drug under BCS for 
the low solubility in the physiological pH range, which is indicated in the theoretical solubility 
profile in Figure 2.2 relative to the highest approved formulation unit dose of 500 mg67, and also 
the high permeability with an apparent partition coefficient in 1-octanol/water (pH 7.4) buffer 
solution of 23868. 
 27 
 
Figure 2.2 Theoretical solubility profile of CellCept® at pH 1.0-14.0. It was generated based on Henderson–Hasselbalch equation 
and isoelectric point. The pH range between the two blue lines represents the typical physiological pH range, 1.2-6.8. 
 
The absorption process of MMF is complex, exhibiting varying plasma concentration-time profiles 
for the pre-systemically hydrolyzed active metabolite mycophenolic acid (MPA), lag time (Tlag), 
maximal concentration (Cmax), time to maximal concentration (Tmax), as well as double peaks 
at the absorption and post-absorption phases69,70. The systemic appearance, biotransformation, 
transport, bile secretion and gut microbiota metabolism and reabsorption processes are shown in 
Figure 2.3. Considering the low solubility, high permeability nature of a BCS class 2 drug, the 
systemic appearance of MMF as MPA can be significantly affected by the changes in the subjects’ 
GI tract environment i.e. different motility states in fasted condition and fasted vs fed conditions. 
It has been demonstrated that the second MPA peak at the post-absorption phase is usually 
observed 6-12 hours post-dose and corresponds well to food intake times due to enterohepatic 
circulation (EHC)68. Therefore, the major metabolite of MPA, 7-O-MPA-b-glucuronide (MPAG), 
which plays a crucial role in EHC, should also be quantified, despite being pharmacologically 
inactive. Variations of any factors in the MPA/MPAG EHC can impact the variability of the second 





Figure 2.3 Overall outline of MMF PK in human body. The red, yellow, blue and green arrows indicate the process of systemic 
appearance, enterohepatic circulation (EHC), disposition, and excretion, respectively. The MMF immediate release drug product 
undergoes rapid disintegration and release process into the gastrointestinal (GI) tract after oral administration before fully dissolved 
in the acidic gastric fluid. Then it permeates the upper GI mucosal cell membrane and is pre-systemically hydrolyzed into the 
pharmacologically active compound mycophenolic acid (MPA) by carboxylesterase 2 (CES2)71. At clinically relevant 
concentration, MPA is 97% bound to plasma albumin. The unbounded MPA is uptaken into the liver primarily by OATP before 
converted into the 7-O-MPA-b-glucuronide (MPAG) and other metabolites mainly by UGT1A9 and UGT2B772,73. MPAG is then 
actively transported to the gallbladder by MRP274, released to duodenum with bile secretion for the conversion back to MPA in the 
gut by microflora. With regard to the overall mass balance, orally administered radiolabeled MMF resulted in ~87% recovery of 
the administrated dose as MPAG, ~6% recovered as other metabolites in the urine and 6% recovered in feces. Negligible amount 
of drug is excreted as MPA (less than 1% of dose) in the urine68. 
 
 
Figure 2.4 Potential factors contributing to MPA PK variability.  
 
Like many other highly variable (HV) drugs, whose within-subject variability (%CV) in 
bioequivalence (BE) metric(s) Cmax and/or AUC >= 30% by definition75,76, the 90% confidence 
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interval (CI) around the geometric mean ratio (GMR) of the test MMF/reference MMF of Cmax 
and AUC would inevitably exceed the BE limits (80%-125%)77 with 18-24 (a common number of 
subject enrollment) subjects under two one-sided tests (TOST)78 procedure as shown in Figure 2.5. 
As the width of the 90% CI depends upon the number of subjects in the study and the variability 
of the BE metrics, it’s natural to either increase the number of subjects enrolled for the BE (as 
shown in Table 2.1) or adjust the BE limits using Reference-Scaled Average Bioequivalence 
(RSAB, -ln(1.25) σWR/σW0 <=(µT-µR)<=ln(1.25) σWR/σW0, where σ2WR  and σ2W0 are the population 
WSV of the reference formulation and a pre-determined constant set by the regulatory agency, 
respectively) instead of the traditional Average Bioequivalence (ABE, -ln(1.25)<=(µT-
µR)<=ln(1.25), where µT and µR is the population average response of the log-transformed measure 
for the test formulation and reference formulation, respectively) based on the WSV79. For example, 
Patel et al80 and Almeida et al81 recruited 126 and 103 healthy subjects for BE study under fasting 
conditions, respectively, due to the high WSV of MMF. However, increasing the number of 
subjects is time-consuming and cost-expensive, and there are still some controversies in terms of 
the selection of the value of σW0, a better approach that can tell product difference between test 
and reference formulation of MMF or even the HV drugs without the confounding effect of WSV 
would potentially be a new BE test standard. 
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Figure 2.5 The 80–125% BE limits are represented along the x-axis as two “goal posts.” The BE limits are compared to the 
hypothetical 90% CIs of the test/reference BE measure GMRs for two drugs, a drug with normal variability (Drug A) and an HV 
drug (Drug B). The 90% CIs of the two drugs are represented by colored bars. For drug A (normal variability), the 90% CI (green 
bar) meets the BE limits. For drug B (HV), the 90% CI (red bar) fails to meet the acceptance limits. As the width of the CI is 
influenced by the number of study subjects, in the hypothetical case of drug B, it is likely that the study would have met the BE 
limits if more subjects had been used79. 
 
Table 2.1 The Number of Study Subjects Required to Show BE with 80% Power is a Function of WSV and GMR (Sample Size 





Sample size for a two-way crossover 
study 
Sample size for a four-way fully replicated 
crossover 
15 
100 10 6 
105 12 8 
110 20 12 
30 
100 32 18 
105 38 20 
110 68 36 
45 
100 66 34 
105 80 42 
110 142 72 
60 
100 108 56 
105 132 66 
110 236 118 
75 
100 156 80 
105 190 96 
110 340 172 
 
As MMF is a classic example of drugs with EHC, a large number of models have been developed 
to characterize the PK profiles of MMF with the emphasis on the modeling of EHC. Figure 2.6 
provides a summary of the schemes of previous models with the inclusion of EHC. Because MMF 
is also a member of BCS class 2 drugs, the variability of systemic appearance cannot be ignored. 
However, there is no model that focuses on quantifying the variability of MMF systemic 
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appearance in plasma in the form of MPA to date. Since the systemic appearance PK parameters 
are good indicators of BE metrics especially Cmax, a model that is designed to explore the WSV 
of BE metrics (Cmax) from the aspect of a more mechanistic level, aka the intra-individual 
variability of PK parameters, would aid in developing a novel BE test methodology by better 
accounting for the WSV. 
 
Figure 2.6 Schematics of MMF PK models EHC. 3-compartment EHC model based on a 1-compartment disposition model82. (b) 
Proposed EHC, 2-compartment structural model with first-order absorption with a lag time (tlag)83. (c) 4-compartment model, with 
rate constant describing transfer from fourth to first compartment84. (d) Chain compartment model (intestinal, gallbladder, central 
and peripheral compartments for MPA and central compartment for MPAG85. (e) 5-compartment drug and metabolite EHC model 
with MPA and MPAG plasma concentrations simultaneously86. (f) 2-compartment model with linear elimination, with MPAG and 
MPA acyl-glucuronide (AcMPAG) produced from the central compartment with EHC of MPA via the two metabolites87. (g) 2-
compartment model accounts for the EHC of MPA. The absorption of MPA was described with two first-order processes with a 
short and a long tlag and subsequent first-order elimination88. Abs comp = absorption compartment; Cm = concentration of MPAG 
in central compartment; ET = gallbladder emptying time; Gall = amount of MPAG in gallbladder compartment; Gut = amount of 
MPA in gut compartment; k = first-order rate constant; kxy = transfer rate constant from compartment x to y; ka = absorption rate 
constant; kbile = biliary excretion rate; kd = excretion rate constant into gallbladder; kGB = rate constant for the release of recirculated 
MPA from MPAG and AcMPAG; km = formation rate; kr,m = renal excretion rate of MPAG; t½,abs = absorption half-life; tgap = 
expulsion time of gallbladder; tGB = time of gallbladder compartment opening; Vm = volume of MPAG in central compartment 
 
This analysis is aimed at: 
1) characterizing MMF PK profiles especially the absorption phase by developing POPPK 
models in liver transplanted patients; 
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2) mechanistically exploring the relationship of the intra-individual variability of MMF PK 
parameters with the WSV of MMF BE metrics (Cmax); 
3) providing insights into the development of a novel BE test for BCS class 2 HV. 
 
2.2 Method 
2.2.1 Clinical study design 
A total of 81 adult patients (71 males and 10 females) receiving liver transplantation at Organ 
Transplantation Center in Ruijin Hospital were enrolled in the study. The study protocol was 
approved by the regional ethics committee (Ruijin Hospital, Shanghai Jiaotong University School 
of Medicine) and was performed in accordance with the Declaration of Helsinki and Chinese 
guidelines for good clinical practice. All the patients gave informed consent before inclusion. The 
demographic and pathophysiological data were collected retrospectively. 
 
The immunosuppressive medications consist of MMF (CellCept®, Roche), tacrolimus (Prograf, 
Fujisawa) and corticosteroids. One gram of MMF was given within 6 hours before liver 
transplantation. After the surgery, dose of MMF was adjusted based on the occurrence of side 
effects. Tacrolimus was orally administrated with an initial dose of 0.1 mg/(kg*day) and was then 
adjusted to achieve a steady-state trough concentration of 10-15 mg/ml in the first week and 5-10 
ng/ml thereafter. An injection dose of 500 mg of methylprednisolone was given during anhepatic 
period and tapered afterwards. After 7 days post first dose, prednisone was used at 20 mg daily 
and then further tapered according to the protocol. Blood samples were collected at 0-12 hr after 
MMF administration at each visit. The plasma concentrations of MPA and its metabolites were 
determined by HPLC assay. 
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2.2.2 Population PK model 
Two population models have been developed based on the data collected from the clinical study 
above. The first model, which only uses MPA plasma concentration as observations, is intended 
to focus on the kinetics of systemic appearance, while the second model, which simultaneously 
model MPA and MPAG plasma concentration-time profiles, was designed for the kinetics of the 
second peak post-absorption. We assumed there are no impacts from the co-medications on the 
PK profiles of the MMF. The bioavailability of MMF was assumed to be 1, because the mean 
absolute bioavailability of oral MMF relative to intravenous MMF based on MPA AUC was 
reported to be 94% in 12 healthy volunteers68. The individual PK parameters at each visit are 
expressed as below: 
 
Where   represents the PK parameter value of the ith individual at visit j; 
            represents the population mean of the PK parameter; 
            represents the deviation of the individual mean of the PK parameter from its population  
           mean, aka the inter-individual variation (IIV); 
            represents the deviation of  from the individual mean of the PK parameter, aka the 
           Inter-occasion variation (IOV).  
Off diagonal element of the covariance matrix are all zeros. 
The expectation maximization (EM) estimation method was employed due to the sparse sampling 
scheme. 
Continuous covariates are scaled by the population median before incorporated as power function 
in Equation 2.2 and the impact of binary covariate are expressed in Equation 2.3 as below: 
 











Where  represents the PK parameter value of the ith individual; 
            represents the population mean of the PK parameter; 
            represents the base line covariate value of the ith individual; 
            represents the population median of the corresponding covariate; 
            represents the covariate effect. 
The metabolism-related kinetics were estimated as parameter(s) based on the data collected from 
the liver transplanted patients rather than using some pre-determined constants to describe the 
metabolism process as previous models. 
Due to the insufficiency of the data, the impact of covariates was tested by one covariate at a time. 
The population modeling work was performed on NONMEM in a parallel computing fashion and 
the visualization plots were generated by R. 
 
2.3 Result 
2.3.1 Exploratory data analysis 
The demographics and clinical test information of liver transplanted recipients are numerically 
summarized in Table 2.2 and the corresponding distribution of each item is graphically 












Table 2.2 Demographics and clinical test info of liver transplanted recipients 
Characteristics Number or median (range) 
Gender (male/female) 71/10 
Age (yrs) 49 (14-76) 
Weight (kg) 66 (37-87) 
ALT NA 
AST NA 
Albumin (g/L) 35 (23-46) 
Creatinine (µmol/L) 71 (37-181) 




Figure 2.7 Distribution of total visit times (A), duration of study (B), age and clinical test (C). WT: Body weight, ALT: Alanine 
transaminase, AST: Aspartate transaminase, ALB: Albumin, CREA: Creatine, TBIL: Total bilirubin, HB: Hemoglobin 
 
 
Figure 2.8 Plasma concentration (scaled by dose)-time of MPA, MPAG, AcMPAG of all the subjects at all the visits (left panel) 
and plasma concentration (Scaled by dose)-time of MPA, MPAG, AcMPAG of Subjects No. 52 at four visits (right panel). The 




Figure 2.9 Distribution of Cmax0-10 hrs (left panel) and AUC0-10 hrs (right panel) of MPA scaled by dose at all visits for all the 
subjects. 
 
Table 2.3 The least sample sizes of different study designs if the test and reference MMF have the same CV (0.486), GMR 0.95, 
90% CI and the target power is 0.8. 
Design Sample size 
2 x 2 crossover study 94 
2 x 2 x 4 fully replicated crossover study 48 
2 x 2 x 3 partially replicated crossover study 70 
 
A total of 81 liver transplanted recipients were enrolled, among whom 71 were males and 10 were 
females. 35 of them only had one visits and for subjects who had multiple visits the longest 
duration of the study could take up to 2 years after the first dose. The distributions of age and 
clinical test, along with total visit times and duration of study were visualized in Figure 2.7. The 
left panel of Figure 2.8 showed the overall variability of plasma concentration-time profiles and 
the right panel displayed the WSV of PK profiles via the example of Subject No. 52. All the plasma 
concentrations are scaled by the dose due to the different dose for each individual at each visit. A 
huge difference could be observed when comparing the Cmaxs of MPA for Subject No. 52 at 
different visits. As shown in Figure 2.9, if only the data at the first 10 hours post dose was extracted, 
the distribution of Cmax scaled by dose was greatly right skewed with CV 7.03% between subject 
variability (BSV) and 48.6% WSV, scaled AUC with 6.32% BSV and 40.4% WSV, respectively. 
Suppose the test MMF generic product has the same WSV as CellCept, GMR is 0.95, CI is 90% 
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and the target power is 0.8, the least sample sizes of different study designs are calculated in Table 
2.3. 
 
2.3.2 Model selection 
2.3.2.1 Model 1: just modeling MPA plasma concentration 
As MPA is the confirmed pharmacologically active form of MMF, emphasis should be placed on 
characterizing the kinetics of this compound. Due to the insufficiency of the data, EHC could not 
be incorporated when just using MPA plasma concentrations as observations. However, since this 
model was only intended for the systemic appearance (the first peak at the absorption phase) of 
MMF in the form of MPA, it’s acceptable to not include EHC, which is used to describe the second 
peak. Model fitting was assessed by Akaike information criterion (AIC). As shown in Table 2.4, 
the best model was NO. 17 model, that is the two-compartment disposition model of MPA with 
IOV from KA, K20 and V2. Figure 2.10 and Table 2.5 provided the description of the optimal 
model graphically and numerically, respectively. When checking the effects of baseline covariates 
on the MMF PK profiles, albumin, total bilirubin, and hemoglobin had significant impact on K20, 
V2, and KA, respectively, as displayed at Table 2.6.  
 
2.3.2.2 Model 2: simultaneously modeling both MPA and MPAG plasma concentrations 
Considering the presence of the second peak, it’s still worthwhile to characterize EHC by 
simultaneously modeling both MPA and MPAG plasma concentrations. The optimal model 
without the inclusion of IOV in this case was Model No.5, that is MPA two-compartment 
disposition with lag time and MPAG one-compartment disposition without the gallbladder 
compartment in EHC. Given the data collected, it’s only sufficient to exam the IOV one parameter 
at a time. As displayed in Table 2.7, inclusion of IOV in terms of Tlag, KA, K23, and K31 could 
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significantly improve the model fitting. Table 2.8 and Figure 2.11 displayed the parameter 
estimation and the diagram of the optimal model Model No.5, respectively. 
 
Table 2.4 A summary of various models just modeling MPA plasma concentration. 
No. Description AIC Note 
1 1-COMP 793.250 Residual error 56.4% 
2 2-COMP 610.269 K20 IIV 0, Residual error 45.8% 
3 2-COMP + Tlag 520.012 Tlag and K20 IIV 0, Residual error 40.5% 
4 2-COMP + Tlag IOV 514.894 Tlag and K20 IIV 0, considerable IOV, residual error 37.2% 
5 2-COMP + Tlag + KA IOV 499.108 Tlag and K20 IIV 0, considerable IOV, residual error 37.7% 
6 2-COMP + Tlag + K20 IOV 427.929 Tlag, K20, and K32 IIV 0, considerable IOV, residual error 34.0% 
7 2-COMP + Tlag + V IOV 431.849 K20 and K23 IIV 0, considerable IOV, residual error 34.1% 
8 2-COMP + Tlag and KA IOV 492.026 Tlag IIOV 0, negligible K20 IIV, IOV KA > Tlag, residual error 
36.7% 
9 2-COMP + Tlag and K20 IOV 408.878 Tlag, K20 and K32 IIV 0, IOV K20 > Tlag, residual error 30.3% 
10 2-COMP + Tlag and V IOV 419.997 K20, K23, and Tlag IIV 0, considerable IOV, residual error 31.0% 
11 2-COMP + Tlag + KA and K20 IOV 395.128 Tlag, K20 and K32 IIV 0, IOV KA > K20, residual error 31.4% 
12 2-COMP + Tlag + KA and V IOV 400.812 Tlag, K20 and K32 IIV 0, considerable IOV, residual error 31.1% 
13 2-COMP + Tlag + K20 and V IOV 414.239 Tlag, K20 and K32 IIV 0, considerable IOV, residual error 32.9% 
14 2-COMP + Tlag, KA and K20 IOV 402.550 Negligible Tlag and K20 IIV, IOV KA > K20 > Tlag, residual error 
30.9% 
15 2-COMP + Tlag, KA and V IOV 394.630 Tlag, K20 and K23 IIV 0, considerable IOV, residual error 29.9% 
16 2-COMP + Tlag, K20 and V IOV 414.686 AIC higher than No. 13 
17 2-COMP + KA, K20 and V IOV 392.661 Tlag, K20 and K32 IIV 0, considerable IOV, large KA IOV, 
residual error 30.7% 
18 2-COMP + Tlag + K23 IOV 510.884 Tlag IIV 0, considerable IOV, residual error 38.4% 
19 2-COMP + Tlag + K32 IOV 502.127 Small Tlag and K20 IIV, considerable IOV, residual error 35.3% 
20 2-COMP + Tlag and K23 IOV 511.032 Negligible Tlag IIV, small Tlag IOV, considerable K23 IOV, 
residual error 37.6%, AIC higher than No. 18 
21 2-COMP + Tlag and K32 IOV 492.238 Tlag IIV 0, negligible K20 IIV, small Tlag IOV, considerable K32 
IOV, residual error 34.6% 
22 2-COMP + Tlag + KA and K23 IOV 489.308 Tlag IIV 0, considerable KA and K23 IOV, residual error 36.4% 
23 2-COMP + Tlag + KA and K32 IOV 480.103 Tlag IIV 0, considerable IOV, residual error 32.5% 
24 2-COMP + Tlag + K20 and K23 IOV 429.823 K20 and K32 IIV 0, considerable IOV, residual error 33.5%, AIC 
higher than No. 6 
25 2-COMP + Tlag + K20 and K32 IOV 436.186 K20 and K32 IIV 0, considerable IOV, residual error 34.2%, AIC 
higher than No. 6 
26 2-COMP + Tlag + V and K23 IOV 423.536 Tlag, K20 and K32 IIV 0, considerable IOV, residual error 32.8% 
27 2-COMP + Tlag + V and K32 IOV 438.672 K32 IIV 0, negligible K20 IIV, small Tlag IIV, considerable IOV, 
residual error 34.2%, AIC higher than No. 7 
28 2-COMP + Tlag + K23 and K32 IOV 491.730 K23 IIOV 0, small Tlag IIV, considerable IOV, residual error 
34.4% 
29 2-COMP + Tlag, KA, and K32 IOV 502.635 AIC higher than No. 8 
30 2-COMP + KA, V and K23 IOV 397.443 Tlag, K20 and K32 IIV 0, considerable IOV, large KA IOV, 
residual error 30.4% 




Figure 2.10 Diagram of the best model when just modeling MPA plasma concentrations. 
 
Table 2.5 Parameter estimation of the optimal model just modeling MPA plasma concentration profiles 
Parameters Estimates (95% CI) IIV (%RSE) IOV (%RSE) 
KA (/hr) 1.10 (0.640-1.89) 0.429 (73.0) 1.18 (76.5) 
Tlag (hr) 0.438 (0.415-0.463) 0 0 
K20 (/hr) 0.611 (0.403-0.927) 0 0.132 (49.1) 
K23 (/hr) 0.481 (0.298-0.775) 0.260 (40.4) 0 
K32 (/hr) 0.122 (0.0758-0.198) 0.168 (26.3) 0 
V2 (L) 39.25 (25.28-60.95) 0 0.173 (123) 
Residual Estimates (% RSE)   
MPA (%) 30.7 (4.98)   
 
Table 2.6 A summary of various models checking on the impact of baseline covariates 
No. Description OBJV 
1 ALB-KA 364 
2 ALB-K20 363 
3 ALB-V2 392 
4 ALB-Tlag 368 
5 ALB-K23 391 
6 ALB-K32 368 
7 SEX-KA 368 
8 SEX-K20 370 
9 SEX-V2 369 
10 SEX-Tlag 376 
11 SEX-K23 415 
12 SEX-K32 364 
13 WT-KA 368 
14 WT-K20 369 
15 WT-V2 367 
16 WT-Tlag 379 
17 WT-K23 368 
18 WT-K32 368 
19 CREA-KA 367 
20 CREA-K20 366 
21 CREA-V2 367 
22 CREA-Tlag 521 
23 CREA-K23 371 
24 CREA-K32 369 
25 ALT-KA 373 
26 ALT-K20 400 
27 ALT-V2 373 
28 ALT-Tlag 369 
29 ALT-K23 373 
30 ALT-K32 373 
31 AST-KA 371 
32 AST-K20 383 
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33 AST-V2 372 
34 AST-Tlag 373 
35 AST-K23 374 
36 AST-K32 373 
37 TBIL-KA 365 
38 TBIL-K20 368 
39 TBIL-V2 363 
40 TBIL-Tlag 372 
41 TBIL-K23 365 
42 TBIL-K32 398 
43 HB-KA 363 
44 HB-K20 380 
45 HB-V2 368 
46 HB-Tlag 373 
47 HB-K23 374 
48 HB-K32 369 
 
Table 2.7 A summary of various models simultaneously modeling both MPA and MPAG plasma concentrations 
No. Description OBJV Note 
1 2-COMP MPA + 1-COMP MPAG 306 Negligible K20 IIV, residual: MPA= 49.4%, 
MPAG = 19.5% 
2 2-COMP MPA + 1-COMP MPAG + EHC + No 
Gallbladder 
300 Negligible K20 IIV, K31 IIV = 0, VMPAG 
IIV = 0, residual: MPA= 49.3%, MPAG = 
19.5% 
3 2-COMP MPA + 1-COMP MPAG + EHC + Gallbladder 299 Negligible K20 K34, and K41 IIV, PMPAG = 
97.7%, VMPAG IIV = 0, residual: MPA= 
49.1%, MPAG = 19.5% 
4 2-COMP MPA + 1-COMP MPAG + Tlag 245 Negligible K20 IIV, Tlag IIV = 0, residual: 
MPA= 44.4%, MPAG = 20.2% 
5 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + No 
Gallbladder 
226 Negligible K20 IIV, K31 and VMPA IIV are 
0, PMPAG = 97.6%, residual: MPA= 43.0%, 
MPAG = 19.6% 
6 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + 
Gallbladder 
230 Negligible K20 K34, and K41 IIV, PMPAG = 
99.2%, VMPA and VMPAG IIV = 0, residual: 
MPA= 43.2%, MPAG = 19.6% 
7 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + Tlag 
with IOV 
212 Negligible K20, K23, and K31 IIV, Tlag: IIV 
= 0 and considerable IOV, PMPAG = 97.3%, 
residual: MPA= 40.6%, MPAG = 19.6% 
8 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + KA 
with IOV 
187 Negligible K20, K31, and K30 IIV, KA: IOV 
significantly higher than IIV, PMPAG = 
96.9%, residual: MPA= 39.8%, MPAG = 
19.2% 
9 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + K23 
with IOV 
66.0 Negligible K20 and K31 IIV, low Tlag IIV, 
K23 IOV significantly higher than IIV, 
PMPAG = 99.4%, residual: MPA= 37.1%, 
MPAG = 16.4% 
10 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + K20 
with IOV 
62.8 Negligible K31 and Tlag IIV, K23 IIV = 0, 
K20 IOV significantly higher than IIV, 
abnormally low PMPAG = 3.97%, residual: 
MPA= 43.4%, MPAG = 16.0% 
11 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + K31 
with IOV 
-1.52 Negligible K20 IIV, PMPAG = 97.8%, K23 
IIV = 0, K31 low IIV and considerable IOV, 
residual: MPA= 40.2%, MPAG = 13.7% 
12 2-COMP MPA + 1-COMP MPAG + Tlag + EHC + K30 
with IOV 
65.5 Negligible K31 and VMAPG IIV, low Tlag 
IIV, abnormally low PMPAG = 16.2%, K20 
IOV significantly higher than IIV, residual 
MPA = 43.4%, MPAG = 16.0% 
PMPAG = K23/(K23 + K20) 
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Table 2.8 Parameter estimation of the optimal model simultaneously modeling both MPA and MPAG plasma concentrations 
Parameters Estimates (95% CI) IIV (%RSE) 
KA (/hr) 0.700 (0.562-0.871) 0.315 (38.1) 
Tlag (hr) 0.380 (0.310-0.466) 0.324 (22.8) 
K20 (/hr) 0.0284 (0.0265-0.0305) 0.0000291 
K23 (/hr) 1.14 (0.937-1.38) 0.221 (21.5) 
K25 (/hr) 1.03 (0.621-1.72) 1.32 (33.6) 
K52 (/hr) 0.0120 (0.00681-0.0213) 1.89 (38.6) 
K31 (/hr) 0.0474 (0.0300-0.0758) 0 
K30 (/hr) 0.125 (0.0973-0.160) 0.324 (22.8) 
V2 (L) 21.1 (17.5-25.5) 0 
V3 (L) 11.0 (8.67-14.0) 0.135 (52.0) 
Residual Estimates (% RSE)  
MPA (%) 43.0 (4.84)  
MPAG (%) 19.6 (4.90)  
 
 
Figure 2.11 Diagram of the models when simultaneously modeling MPA and MPAG plasma concentrations. The flow of the 
optimal model Model No.5 was represented with solid arrows. The light blue square and dashed arrows are the gallbladder 
compartment and the corresponding kinetics used in Model No.6. 
 
2.3.3 Model evaluation 
The diagnostic plots of Model 1 look not so perfect mainly due to exclusion of the EHC (Figure 




Figure 2.12 Goodness-of-fit plots (A-D) and visual predictive check (VPC) plot (E) when just modeling MPA without EHC. LNDV: 
logarithm of the observed MPA plasma concentration; IPRED: individual prediction of the MPA plasma concentration after taking 
the logarithm. PRED: logarithm of the population prediction of MPA plasma concentration. CWRES: conditional weighted residual 
errors. The solid blue line represents the median observed MPA plasma concentration, and the dark orange area around it represents 
a simulation-based 95% confidence interval for the median. The observed 5% and 95% percentiles are presented with dashed blue 




2.4 Conclusion and discussion 
Considerably more attention should be drawn to how to better conduct BE studies for HV drugs. 
Firstly, HV drug products constitute a disproportionately high percentage of drug product 
submissions among the failed BE studies in one of the FDA statistics79. While HV drugs only 
appear to represent about 20% of ANDAs evaluated by FDA, 45% of the failed BE studies 
reviewed at FDA from 2009 to 2012 belong to HV drugs based on Table 2.979. Secondly, the 
current approaches to addressing the high failure rate issue of HV drug are economically and 
scientifically unfriendly. As summarized in Table 2.10, among the 45% of the failed BE studies 
mentioned above, 91% of the initially failed ANDAs met the BE limits by increasing sample size 
in two-way crossover BE study and 7% of them passed the BE tests by changing to three-way 
study design and RSABE79. The large sample size required would increase the costs of generic 
drugs, perhaps more significantly lead to unnecessary human testing, and deter the development 
of new generic products. Furthermore, the scientific debate of setting the regulatory constant and 
cutoff for RSABE limits the wide application of this approach in BE studies79. Therefore, a novel 
methodology that is targeted to solve the high WSV of BE metrics (Cmax, AUC) is highly 
desirable. 
 
Table 2.9 Number of Failed BE Studies Reviewed at FDA’s OGD Since the “All Bioequivalence Studies” Rule Became Effective 
in July 2009 till 2012. 79 
Description BE Studies ANDAs Number Percent of total Number Percent of total 
WSV of AUC and Cmax≥30% 92 45 45 37 
WSV of AUC and Cmax<30% 113 55 76 63 






Table 2.10 Changes Made to the Study Design or Formulation to Achieve Successful Pivotal BE Studies of HV Drugs after the 
Initial BE Studies Failed to Meet the Acceptance Criteria79 
Change made No. of ANDAs Percent 
Increase in sample size two-way crossover BE study 41 91 
Changed to three-way study design and RSABE 3 7 
Reformulated 1 2 
Total 45 100 
 
The WSV of BE metrics (Cmax and AUC) can be largely explained by the intra-individual 
variability of systemic appearance related PK parameters in the case of HV drugs. As we know, 
the rate and extent of drug dissolution and subsequent absorption rely on the characteristics of GI 
physiological environment such as hydrodynamics, gastric emptying rate, intestinal transit, GI pH, 
buffer capacity and the fasted vs fed state of the GI tract, as well as the physicochemical properties 
of the drug and the properties of dosage forms89,90. Hence, a slight change in physiological factors 
may give rise to significant variabilities in the process of drug oral uptake and systemic appearance. 
This may be especially pronounced for drug molecules suffering from a low aqueous solubility 
but showing a high intestinal permeability, classified as BCS class 2 compounds5, which are likely 
to be HV drugs. For the IR products of these HV drugs, dissolution could be the rate-limiting step 
of their absorption, rendering them super sensitive to environmental changes at absorptive sites.  
Consequently, high variabilities are commonly observed in their dissolution and absorption 
profiles even for the same individual at different measuring times (high intra-individual variability) 
and contribute greatly to the WSV of BE metrics. These high variabilities can be represented as 
the intra-individual variability of systemic appearance from the aspect of PK. Simulation of 
luminal dissolved drug concentration based on GI physiology is therefore one of the key 
determinants of reasonable prediction of drug absorption. 
 
The intra-individual variability of systemic appearance related absorption PK parameters can be 
partly attributed to different states under fasted conditions. The dynamics of GI transit and luminal 
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pH fluctuation and the underlying physiological basis has been described in detail in Section 1.3 
and 1.2.2, respectively. Oral dosing under the fasted conditions can occur at one of the very 
different states of MMC, and thus results in high variability.  
 
While under postprandial conditions, the motility and secretion pattern vary greatly from those 
under inter-digestive conditions. The stomach mechanically breaks down the ingested food into 
small particles to enhance digestion like a homogenizer. The pylorus remains closed for prolonged 
periods and acts as a sphincter that controls the amount and size of food particles that can exit the 
reservoir, the stomach, in the intermittent partial openings. The gastric emptying rate depends on 
both the physical and chemical characteristics of the meal with a rate of 200 kcal/hr on average: 
liquids empty most rapidly; solids empty only after a lag phase. The cutoff particle size to be held 
back or to be delivered to the duodenum is 1-2 mm. Meanwhile, motility events in the small 
intestine become more frequent, with patterns designed to mix the meal with intestinal secretions 
and to maximize exposure of the digested nutrients to the absorptive mucosa. Intestinal transit is 
slowed in proportion to the number of calories presented to the intestine. The gallbladder serves 
to store and concentrate bile coming from the liver in the period between meals. Postprandial 
gallbladder contraction coincides with gastric emptying. The entry of the meal into the duodenum 
triggers the secretion of a bolus of concentrated bile with the entry of dietary lipids into the small 
intestine10. 
 
In this study, two population PK models have been developed with the emphasis on exploring the 
variability of systemic appearance and EHC of MMF. The first model only employed MPA plasma 
concentrations as observation and investigated the intra-individual variability of PK parameters in 
the form of IOV. The second model used both MPA and MPAG plasma concentration profiles to 
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further check EHC. The effect of IOV of PK parameters was checked only one at a time in the 
second model due to data insufficiency. The results of both two models showcased that the intra-
individual variability plays a predominant role instead of IIV in terms of variability of absorption-
related PK parameters. The high intra-individual variability of absorption-related PK parameters 
would be expected because the timing of drug administration and sampling is a mix of fasted and 
fed states and there is no knowledge of motility state and MMC phases at the time of dosing and 
the variable duration of MMC cycle. 
 
Surprising as it may look at first glance, GE is likely to be the rate-limiting step in the systemic 
appearance process of CellCept and hence accounts for the intra-individual variability of its 
systemic appearance. MMF has to go through the disintegration, release and dissolution in the 
stomach, gastric emptying, transport into the mucosal cell, and conversion to MPA before showing 
up in the circulating system in the form of MPA. Given the fact that 1) CellCept is the only drug 
product of MMF used in this study; 2) CellCept is IR by design; and 3) rapid and stable dissolution 
in the stomach reported by Scheubel et al91, negligible variation should be anticipated from the 
release and dissolution process of CellCept. Also considering the high permeability and super low 
pKa value of the morpholino group, it would be natural to speculate that CellCept is quickly 
transported into the mucosal cells of the proximal small intestine lumen, once being dissolved and 
emptied from the stomach. Finally, due to a complete and rapid pre-systemic metabolism, the 
conversion of MMF to MPA would not introduce significant further variation. Taken together, all 
the systemic availability events of CellCept are controlled by gastric emptying and Cmax can be 
seen as a function of gastric emptying. The indirect evidence in a previous publication showed that 
plasma Cmax/AUC was negatively associated with time to MMC phase 3 post dosing in the fasted 
state after a dose of Ibuprofen92. Therefore, it seems mechanistically correct to claim that intra-
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individual variability of MMF systemic appearance is essentially the intra-individual variability of 
GE. 
 
The dominance intra-individual variability possessed over IIV in terms of absorption-related PK 
parameters would suggest the BE studies of MMF from two different perspectives. Firstly, dosing 
under fed conditions is recommended for the in vivo clinical BE studies. Because less WSV of BE 
metrics is anticipated under fed conditions with the same meals distributed to each subject 
compared with under fasted conditions due to the randomness of dosing and sampling time relative 
to the three MMC phases, assuming there are no food-drug interactions. In addition, the bile 
secretion rate is well regulated under fed conditions to reduce the variations in EHC. Secondly, a 
novel predictive in vitro BE test only measuring product difference would be a new trend because 
in vivo clinical BE studies are greatly confounded by the large GI variations. Obviously, the impact 
of BSV is removed from an in vitro test to simplify the analysis. In the case of MMF, as discussed 
previously, the WSV of systemic appearance, though large, is actually the intra-individual 
variability of GE, and the product difference is significantly confounded with random GI motility. 
Despite of the huge intra-individual variability of EHC, it only explains the variation of the second 
peak in post absorption phase, which is also related with the GI physiological dynamics and the 
time of food consumption post dosing. Thus, a predictive dissolution test comparing the profile of 
the test formulation to that of the innovator MMF product with sufficient simulation of Gastric 
emptying dynamics would be a desirable surrogate. If the release and dissolution rate of the test 
MMF formulation is rapid like the original CellCept (85% dissolved within 15 mins), then 
equivalent dissolution profiles would indicate bioequivalence of the test and reference MMF. As 
for other HV drug products, an in vitro dissolution test sufficiently simulating GI physiological 
dynamics for oral systemic availability (absorption) would also serve the BE test purpose. 
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While the predictive in vitro BE test has gained increasing attention since the development of the 
BCS classification system, it is not widely accepted even today. This is because current dissolution 
tests do not take full advantage of the extensive available GI physiologic information. For instance, 
the static fasted intestinal pH values of FaSSIF (6.5) and USPSIF (6.8) are embodied as a strong 
buffer capacity, that is a 5 and 7.7 times higher capacity than human intestinal fluid, 
respectively93,94, which apparently fails to reflect the real in vivo GI physiological conditions, let 
alone to capture the characteristics of drug dissolution, absorption and systemic exposure kinetics 
(Cmax, AUC, Tmax). These routine methodologies are more suitable for quality control purposes 
and are only used as tools to understand the effects of formulation and processing changes95, so a 
new methodology incorporating the physiologically relevant GI information is desired. A good 
starting point would be a typical fasted BE condition, but could evolve into tests simulating the GI 
environment of patients and special populations. Some in vivo tests may be required for final 
assurance of performance in patients, but the in vitro dissolution test would be the mainstay of 
product development and quality control. 
 
Although there’s a sea of MPA population models attributed to EHC of MPA96, the uniqueness of 
the two models developed in this study lies:  
1) for the first time focusing on the complicated absorption process of MMF as a BCS class 
drug, relating the intra-individual variability of the systemic appearance PK parameters to 
the WSV of BE metrics and mechanistically explaining the intra-individual variability from 
the aspect of GI physiology dynamics;  
2) introducing IOV to the metabolism process rather assume a static MPA clearance rate with 
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fixed ratio of converting to MPAG: being cleared via other routes, considering the subject 
are liver transplanted recipients and time-varying Cmax and AUC have been noted among 
these type of patients in FDA drug label of CellCept68. 
 
Significant conclusion can be drawn with regard to the complicated MMF absorption process by 
leveraging the data at hand, however, the variance in the population model could be better 
quantified if:  
1) more frequent sampling schema was designed for the absorption phase; 
2) food intake time relative to MMF dosing was well recorded;  
3) the clinical biochemistry covariates were collected at least at each visit;  
4) the protein-bounded MPA were determined rather than just the total MPA, since MPA 
is highly bounded to albumin. 
 
In the future, we would like to dive deep into the mechanisms of HV drug absorption process by 
further exploring the relationship between GI physiology dynamics and PK variability. Possible 
attempts include utilizing:  
1) SmartPill to record local GI pH fluctuation and motility;  
2) tubes in the GI tract to directly determine the concentrations of dissolved and undissolved 
drug;  




A Special thank you to Hao Chen and Dr. Rose Feng for their generosity in providing the valuable 
CellCept clinical data to make this study possible, and Dr. Yangbin Li for his work in the initial 
analysis of the data. 
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BCS theory employs the physicochemical concept of maximal solubility in GI physiological pH 
range relative to the highest strength and intestinal permeability to represent the behavior of an IR 
solid drug dosage form in the GI tract and further predict the systemic appearance profiles of this 
oral drug product. It has been widely adopted as the criteria for the biowaiver of a generic IR solid 
drug product. FDA has launched a web-based application to facilitate collecting information of 
FDA-approved drug products without the inclusion of drug BCS class. (https://nctr-
crs.fda.gov/fdalabel/ui/search) Considering the enormously high volume of documentations 
regarding drugs designed for oral absorption, it is desirable to harvest BCS classification 
information from various sources online to support pharmaceutical development and clinical 
decision.  
 
However, the information extraction (IE) of drug BCS class is never an easy task. Firstly, the 
relevant solubility profiles and intestinal permeability are scattered in various documents like drug 
labels, regulatory review documents, and literatures. Secondly, a large number of the materials are 
uploaded online as a scanned pdf file, which means people cannot find the BCS info by just 
googling. Thirdly, compared to the structured data, drug BCS class and relevant info are usually 
documented in a more natural, expressive and unstructured way. Fourthly, biomedical documents 
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usually involve heavy use of domain-specific terminology and knowledge, making it difficult for 
a non-pharmaceutical scientist to handle it directly. 
 
Natural language processing (NLP), a confluence of computer science and linguistics, enables the 
extraction of BCS class from a deluge of information and the transformation of the text into 
actionable data that can be quickly visualized and analyzed at different stage of drug development 
via ML/AI algorithm. Some of the major areas of NLP include but not limit to question answering 
system, automatic summarization, machine translation, speech recognition, and document 
classification97. Recently, it also gains popularity among big pharmaceutical companies and bio-
tech organizations. Just to name a few, NLP has been used for effective search for patent 
landscaping and competitive intelligence in Pfizer, discovery potential novel biomarkers and 
phenotypes for diabetes and obesity, from PubMed, clinical trial data, and internal research 
documents in Merck, and text mining EMRs for patient stratification of heart failure risk in BMS98. 
 
The goal of this project is to propose a framework to use text mining technology mainly NLP to: 
extract of the solubility, permeability and/or BCS class information of IR solid oral drug products 
from drug labels, FDA review documents, FDA orange book, and some selected biomedical 
literatures; 
1) identify drug BCS class based on the text mining results in a supervised way; 
2) help build a database carrying drug oral absorption information to further fulfill the BCS 




3.2.1 Documents retrieval 
The scope of the BCS source search included appropriate drug product lists with its active 
pharmaceutical ingredients (APIs), highest strength, text corpora consisting of drug labels, FDA 
review documents, and literatures, knowledge of pharmaceutical sciences. First, search the FDA 
orange book (published on 03/23/2020) thoroughly to get a list of product name, active 
pharmaceutical ingredient (API) and the corresponding highest strength with the inclusion criteria 
regarding the drug products: 1) still on the market; 2) with known strength; 3) oral dosage form; 
4) immediate release; 5) solid. Secondly, query the FDALabel database based on the product 
names acquired in the first step and save the query results; Thirdly, filter the query results from 
the second step with same inclusion criteria mentioned in the first step to obtain all the application 
numbers of the drug products; Fourthly, Crawl the Drugs@FDA website 
(https://www.accessdata.fda.gov/scripts/cder/daf/) automatically according to the application 
numbers compiled in the third step and save all the pdfs files mainly all the labels and FDA review 
documents. Fifthly, add the necessary biomedical literatures found on Web of Science, Pubmed, 
and Research Gate to the large corpus in the fourth step to form a collection of documents, if there 
are no solubility, permeability or BCS class information on the FDA website. Sixthly, narrow 
down the scope of drug products by manually inspecting 1) it’s not absorbed in the oral cavity; 2) 
BCS class has been confirmed by FDA reviewer; 3) it has clear supporting solubility and 
permeability data. Seventhly, convert all the scanned pdf files to plain text for the text data and to 
Microsoft Word for the tabular data using the Optical character recognition (OCR) feature 
provided by Adobe Acrobat to get the raw large corpus for NLP analysis. Eighthly, label the BCS 
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class of each drug substance manually based on my knowledge of pharmaceutical sciences and 
save the classification result as a gold standard for the ML/AL classification models.  
 
3.2.2 Text preprocessing 
Sentence splitting, tokenization and stemming was done sequentially to the raw text corpus. Only 
the sentences satisfying the following conditions were kept:  
• Containing “BCS”, “Biopharmaceutics Classification System”,  
• Containing “solub” and “pH” 
• Containing “permea” and “%” 
• Containing “bioavailability” and “%” but no “relative”, containing “bioavailability” and 
“fraction” but no “relative”, containing “absor” and “gastrointestinal”, containing “absor” 
and “GI”, containing “absor” and “complete” 
• No “rat”, “mice”, “dog”, “monkey”,”pig”, etc 
Assign 80% of the drug substances and the corresponding tokenized sentences to the training 
dataset. 
 
3.2.3 ML/AI model 
The pre-processed text was then transformed into quantifiable data by the algorithm “word2vec”. 
ML algorithms Logistic regression (LR), random forest (RF) and Bi-LSTM were employed to train 
the model and the best models achieved from the training results were applied to the test set to 
predict BCS class.  
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3.2.4 Ontology construction 
The BCS ontology is composed of three components: solubility, permeability, and BCS class. 
“Solubility” specified the solubility profiles numerically (eg. 2.5 mg/mL) or textually (e.g insoluble) 
under certain pH ranges (eg. pH range 1-6.8, physiological pH range, pH 3). “Permeability” 
indicated drug permeability result (eg. high permeability, 100%) in the corresponding form (eg. 
Caco-2 cells, absolute bioavailability). “BCS” represents the direct claim of drug BCS class found 
in the text like BCS Class 2, Class III of the Biopharmaceutical Classification System, et.al. 
 
3.2.5 IE using NER 
Ontology-based name entity recognition (NER) enable to better locate the BCS-related named 
entities to greatly narrow down the scope for analysis. 
The drug BCS class information is extracted as tagging entities as below: 
• Drug tagging: a drug substance library was built based on the list of API and tagged as like 
<DRUG: mycophenolate mofetil> 
• Highest strength tagging: the highest strength of a drug product was acquired from the list 
described in 3.2.1 in the form <DOSE: 500 mg> 
• Solubility tagging: <SOL_RE: 4.27 mg/mL> at <SOL_PH: pH 3.6> 
• Permeability tagging: In 12 healthy volunteers, the mean <PER_SU: absolute 
bioavailability> of oral mycophenolate mofetil relative to intravenous mycophenolate 
mofetil (based on MPA AUC) was <PER_RE: 94%>. 
• BCS class tagging: MMF is a weak base classified as a <BCS: BCS Class II> substance. 
 
3.2.6 Identification of BCS class with NER 
The priority of determining BCS class for a drug product is listed as follows: 
1) If a BCS info is tagged directly, then read the number within the BCS class tagging; 
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2) If there’s no BCS class tagging for a drug substance, then check the solubility: 
• If any numerical results was tagged as SOL_RE then compared the results with highest 
strength (mg) divided by 250 mL to get a binary result in term of solubility either “high” 
or “low”; 
• If the content within the tag SOL_RE doesn’t contain any numbers, then process the text 
via NLP ML/AI algorithm; 
3) If there’s no BCS class tagging for a drug substance, then check the permeability. 
• If any numerical results tagged as PER_RE were higher than 85%, then “high” 
permeability; otherwise “low”; 
• If the content within the tag PER_RE doesn’t contain any numbers, then process the text 
via NLP ML/AI algorithm; 
4) If there’s no BCS class tagging for a drug substance, then identify the BCS class for a drug 




The prediction results were evaluated with gold standard described in the eighth step of 3.2.1 with 
the metrics precision, recall, and F1 scores. 
 
3.3 Results 
3.3.1 Exploratory data analysis 
There are 38118 drug products in the FDA orange book published on 03/23/2020. 21114 of them 
are still on the market. Among these, 21057 drug products with known strength. 14641 of them 
are designed as oral dosage form and 12186 are IR. As shown in Figure 3.1, 820 of the distinct 
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APIs collected from the 11232 solid dosage forms for further analysis. Based on the BCS class, 




Figure 3.1 Summary of drug products in FDA orange book 
 
Figure 3.2 displays how the BCS ontology is tagged in a text corpus after pre-processing. 
 
Figure 3.2 An example of annotated corpus based on BCS ontology. 
 
3.3.2 Model Evaluation 
Table 3.1 showcased that NER using the BCS ontology performed significantly better predictions 
compared with handling the text just with ML/AI models. 
Table 3.1 Evaluation results of the ML/AI and NER models 
Method Class 1   Class 2   Class 3   Class 4   
 Precision Recall F1 Precision Recall F1 Precision Recall F1 Precision Recall F1 
LR 0 0 0 0.33 1 0.5 0 0 0 0 0 0 
RF 0 0 0 1 1 1 0.5 1 0.67 1 1 1 
Bi-LSTM 0 0 0 0 0 0 0.25 1 0.4 0 0 0 
NER 1 1 1 1 1 1 1 1 1 1 1 1 
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3.4 Conclusion and discussion 
NER-based NLP did a nice job on extracting information and identifying drug BCS class from 
unstructured data on a large scale. Classification based on NER is better than classical machine 
learning algorithm combined with deep neural network models.  
 
A well-annotated BCS corpus and ontology can facilitate text mining in the development and 
practice of drug substances in IR solid oral dosage forms on a large scale. In the future, we are 
interested in expanding the NLP approach to the whole drug oral absorption arena like different 






The appendix contains a summary of tangential projects pursued during my PhD studies, though 
not fully completed due to various reasons. They are summarized below for future reference. 
 
Project 1: Stochastic Differential Equation-Based Hierarchical Model of the 
Fluid Volume in the Stomach 
 
Introduction 
The rate and extent of solid oral drug products release, dissolution and absorption depend largely 
on the dynamic fluid volumes along the gastrointestinal (GI) tract. Since the fluid volume in the 
stomach is determined by saliva and gastric secretion, gastric emptying and oral dosing, a model 
built based on the observed fluid volumes in the stomach at given sampling times can be used to 
describe the kinetics of these physiological and drug product related process. This is the basis for 
a more mechanistic approach to predicting drug release, dissolution and subsequent absorption 
profiles. The predictive results are particularly important for the monitoring of highly variable 
drugs with narrow therapeutic windows and the design of bioequivalence studies. Conventionally, 
these physiological parameters are all treated as time-invariant and the fluid volume in the stomach 
is not considered explicitly, however, recent research results demonstrated these physiological 
processes are very dynamic26-31. 
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Stochastic differential equation (SDE) -based hierarchical model is preferred in the dynamic 
system to provide a robust parameter estimation, and serves as a diagnostic tool for structural 
model misspecification or parameter fluctuations. In contrast to the classical ordinary differential 
equation (ODE) based population approach, where intra-individual variability is only assigned to 
measurement errors, the employment of SDE method allows for decomposition of the intra-
individual variability into a system noise term arising from time-dependent or serial correlated 
errors like unknown or incorrectly specified dynamics and a measurement noise term accounting 
for uncorrelated errors such as assay error99. 
 
The aims of this project are (1) to capture the great inter- and intra- individual variability of the 
stomach fluid volume and transit in healthy subjects; (2) to find out the physiological parameter(s) 
representing the dynamics in the stomach by implementation of SDE method and comparing the 




Twelve healthy subjects were enrolled and had their gastric and small intestinal water volume 
measured by magnetic resonance imaging (MRI) scans before and after consumption of 240 mL 
of water at pre-determined intervals for up to 2 hours post-ingestion as shown in Appendix Figure 
1. The SDE- and ODE- based mixed effects morels were implemented and compared using 




Appendix Figure 1: Study diagram 
 
Model assumption 
The stomach compartment was basically modeled with zero-order saliva and gastric secretion 
coefficient Kse and first-order gastric emptying coefficient Kge as depicted in the Appendix Figure 
2.  
 
Appendix Figure 2: Schematic illustration of the structure model for the fluid volume in the stomach. 
 
The first-stage model with SDEs written in state-space form consists of a set of continuous time 
system equations in Equation (1)-(2), and discrete time measurement equations in Equation (3), 
that is, 
For subject i at jth sampling time: 
Continuous time state space stochastic differential equations: 
dXstomachi(t) = (-Kgei(t) x Xstomachi(t) + Ksei)dt                                                   (1) 
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dlogKgei(t) = -α(logKgei(t) - logKgei*) + σwKgedWi(t), Wi(t) – Wi(s) ~ N(0, |t-s|I)   (2) 
Discrete time measurement equations: 
Vstomachij = Xstomachij x (1 + σpropε1) + σaddε2, ε1 and ε2 ~ N(0,1)                        (3) 
Inter-individual variability: 
Kgei* = Kge* x exp(ηKgei), ηKgei ~ N(0, ωKge
2
)                                                           (4) 
Ksei* = Kse* x exp(ηKsei), ηKsei ~ N(0, ωKse
2
)                                                             (5) 
where Xstomach is the stomach fluid volume state variable, Vstomach is the observation variable, 
t is the time variable, σwdW is the system noise, I is the identity matrix, σpropε1 and σaddε2 are the 
heteroscedastic and homoscedastic measurement errors, respectively.  
 
σw is a scaling diffusion term, where W is a standard Wiener process. The possible fluctuations of  
parameter were checked in the scenario of dynamic (1) Kse σwKse, (2) Kge σwKge, (3) Kse and 
Kge σwKse and σwKge by Ornstein-Uhlenbeck diffusion process. We just showed the case of 
time-varying Kge as an example below in Equation (2). If the diffusion term σw is zero, the SDE 
reduces to an ODE. The usual physiological interpretation of the parameters is thereby preserved 
in the SDE model formulation. 
 
The second-stage model describing the inter-individual variability (IIV) is included in the same 
way as for ODEs. The typical individual parameter value are modeled in Equation (4) and (5) as a 
function of the fixed-effect population parameters and random-effect parameters η. The random-
effects η are assumed independent and normal distributed with zero mean and standard deviation 
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ω. The three levels of random-effects diffusion process, measurement error, and IIV are assumed 
mutually independent for all i, t, and j. 
 
Algorithm 
The Extended Kalman Filter (EKF) was implemented to estimate state variables on individual 
level. The first step of this efficient recursive algorithm is called one-step prediction equations, 
which are the optimal (minimum variance) prediction of the state mean and covariance at jth 
measurement, can be calculated by solving the state and state covariance prediction equations from 
measurement time tj-1 until tj, that is, 
 
Next, the EFK one-step output prediction equations are calculated by  
 
The one-step output prediction   is the optimal prediction of the jth measurement before 
that measurement is taken while  is the expected covariance for that prediction.  is thus 
the sum of the state covariance associated with the observed states and the covariance of the actual 
measurement. 
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Finally, the one-step state and state covariance predictions are updated by conditioning on the jth 
measurement using the EKF state update equations, that is, 
 
where  is the updated state estimate,  is the updated state covariance, and Kij is called 
the Kalman gain. The optimal state estimate  is equal to the best state prediction  before 
the measurement is taken plus a correction term consisting of an optimal weighting value times 
the difference between the measurement Yij and the one-step prediction of its value. 
 
Results 
Raw data visualization 
There exist great inter- and intra- individual variability in the observed data in Appendix Figure 3, 




Appendix Figure 3: Great inter- and intra- individual variability were shown in the left and right panel, respectively. Left: Observed 
fluid volume in the stomach (mL) vs Time (min). The blue curve is the locally weighted smoothing line among different subjects 
in the time course and the scattered numbers represent the ID number of each subjects. Right: Individual observed fluid volume in 
the stomach (mL) vs Time (min) 
 
Model Selection 
The three SDE models in the Appendix Table 1 showed significant improvement in goodness of 
fit compared to the traditional ODE model. And the parsimonious model with lowest AIC—SDE 
with dynamic gastric emptying coefficient model was considered to best characterize the time 
course of stomach fluid volume and was chosen for further analysis, implying the fluctuation of 
gastric emptying coefficient might be the driven factor for the system dynamics of fluid volume in 
the stomach. 
Appendix Table 1: A brief summary of the tested models 
Models AIC Diffusion process 
ODE 1416.405 α = 0 and σ
w
=0 

















































Optimal model results 
The estimates of the typical population mean of Kge and Kse are all in line with physiological 
range in the literature in both SDE and ODE. The proportional and additive measurement error 
were decreased from 14.4% to 4.10% and 17.6 mL to 4.74 mL for the fluid volume in the stomach 
compartment by SDE compared with ODE, respectively, indicating a large part of intra-individual 
variability belong to the system dynamics especially the fluctuation of gastric emptying coefficient 
Kge. These serial correlated errors would be ignored and empirically assigned to the measurement 
error if we adopt the traditional ODE method. The relative standard error (RSE) estimates were 
more or less the same for the SDE and ODE models. 
Appendix Table 2: Parameter Estimation of SDE with dynamic gastric emptying rate parameter and ODE 
Model SDE ODE 
Parameters Estimates RSE(%) Estimates RSE(%) 
Physiological 
Kge (/min) 0.0514 25.1 0.0714 9.01 
Kse (mL/min) 1.52 18.6 1.59 13.9 
Intra-individual variability 
 
σwkge(min-1/2) 0.251 13.6 0 na 
αkge(/min) 0.0204 38.9 0 na 
σprop (%) 3.57 24.6 14.4 20.2 
σadd (mL/min) 4.83 12.4 17.7 8.59 
Inter-individual variability 
ωKge (%) 60.6 49.9 27.5 46.2 
ωKse (%) 18.6 na 21.6 na 
RSE = Estimates/SE*100(%), na-not available 
 
The time-varying nature of Kge was shown in the Appendix Table 2 compared to the constant 
estimation in ODE for each individual in this study. This is the estimation of the hidden state based 
on observations at each measurement time, which contributes most to the dynamics of the stomach 
fluid volume system. 
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The one-step individual SDE predictions, updates, and prediction interval are shown together with 
the individual ODE predictions in Appendix Figure 4. The observed discrepancy between the SDE 
and ODE predictions are due to the SDE predictions being conditioned on all previous 
observations and therefore updated at each sampling time (visualized by the vertical lines in the 
SDE predictions). 
 
Appendix Figure 4: Estimation of logrithm of the gastric emptying coefficient Kge at each measurement time for each individual 
based on observed records. 
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Appendix Figure 6: Goodness-of-fit plots (A-D) and visual predictive check of the SDE with dynamic gastric emptying coefficient 
based hierarchical model of the fluid volume in the stomach among healthy subjects with EKF estimation algorithm. DV: observed 
stomach volume (mL). IPRED: individually predicted stomach fluid volume (mL); PRED: population predicted stomach 
volume (mL); WRES: weighted residual errors. 
 
Optimal model diagnostics 
The individual predictions (IPRED) are generated by assuming a new observation based on 
estimated individual estimated in the population, while the population predictions (PRED) are 
targeted to the new observations of a new individual based on the estimated parameter 
distributions. As shown in the A and B plots of Appendix Figure 6, the dots scatter evenly along 
the two sides of the red line y=x when comparing the prediction and observed fluid volume in the 
stomach, indicating a good prediction quality. We also investigated on pattern of the weighted 
residual errors (WRES: (Yij-Yi(j|j-1)/Rj|j-1) and found it didn’t change as the population prediction 
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value and time. This means that the WRES is a white noise. Therefore, the selected optimal model 
was demonstrated to be well developed. 
 
Conclusion and Discussion 
The SDE-based mixed effects model developed from our study successfully characterized the 
volume profiles in the stomach among the healthy subjects and provided a robust approximation 
of the physiological parameters in the very dynamic system. The remarkable intra-individual 
variability could be further decomposed into system dynamic terms and measurement error terms 
in the SDE model instead of empirically assigning all the intra-individual variability to 
measurement error in the traditional ODE method. The system dynamics were best captured by 
the random fluctuation of the gastric emptying coefficient. 
 




An insight into phase 3, the decisive factor of gastrointestinal motility and secretion, helps us better 
predict drug transit and dissolution in gastrointestinal tract and subsequent drug absorption profile. 
This study is primarily aimed at building up a model of duodenal MMC phase 3 motility behavior 




The original manometry data was sampled every 0.1s for 7hrs. For the purpose of course project, 
the data in this study was subsetted by extracting one value out of every 1s during the phase 3 
activity of first MMC cycle after determination at mid-duodenum of one subject. The summary 
info and plot along the time course are displayed below. 
 
 
One may first want to check the potential seasonality since phase 3 is known for regular 
contractions relative to the other two phases. There is an obvious pattern occurring between every 
6 lags and the period of the most prominant frequency in the periodogram is also 6s, indicating a 
mainstream period of 6s per peak in phase 3, which is in concert with the literature claim “10-12 






After differencing by 6 lags, the seasonal pattern disappear in the ACF plot and time plot looks 





A time series data can be decomposed into three components: trend, seasonal and random. It’s 



















Conclusion and Discussion 
1) The SARMA(2,2)×(2,0)6 model has been successfully constructed to simulate the MMC 
phase 3 motility pattern, though some further optimization might be needed to account for 
the extreme peaks; 
2) The unsatisfactory part can be explained as the data has an unstable standard deviation and 
is right skewed. However, many time series analysis methods are built on the assumption 
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of weak stationary: i. constant mean value function; and ii. the autocovariance function 
only depends on the length of time interval function; 
3) In the next step, we will aggregate all the phase 3 manometry data of the subject in mid-
duodenum throughout the 7hrs to get a better idea of the motility pattern along the time 
course accumulate the phase 3 manometry data of all the subjects at different sites along 
the gastrointestinal tract, build up a hierarchical model to investigate the intra- and inter- 
subject variance and find out some significant covariable. 
 
Project 3: Human Proximal Small Intestinal pH Model 
Introduction 
A better characterization of the pH dynamics may help better explain and/or predict the great intra- 
and inter- individual variabilities in the drug dissolution, solubility and absorption profiles. The 
SmartPill motility testing system features an ingestible capsule that measures pressure, pH, transit 
time and temperature as it passes through the entire gastrointestinal tract, making it possible for 
recording the pH fluctuation in the proximal small intestine. This study is primarily aimed at 
building up a model reflecting the pH dynamics in the proximal small intestine based on SmartPill 
data via hidden Markov method. 
 
Data Exploration 
The subset individual pH data used in this study starts right after gastric emptying, and ends when 
the pH reaches a relative stable level. The duration is 30 mins with a sampling frequency of 5s. 
The summary info and plot along the time course are displayed below. The pH fluctuations are 
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great in the beginning and dies down gradually as time goes by. The pH statistics of this person all 
fall into the normal scope14. 
 
Model Building 
The HCl (pH=1-2) is emptied from the stomach into the duodenum in a pulse packet fluid fashion 
and is neutralized by HCO3- (pH=7-7.5) secreted from the duodenal cluster unit, especially the 
pancreas. The intestinal pH is sustained at a reasonable range by the feedback mechanism of human 















1. Lennernas H. Human intestinal permeability. J Pharm Sci 1998; 87(4): 403-10. 
2. Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical 
design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 1996; 
19(3): 359-76. 
3. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release 
Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. U.S. Food and 
Drug Administration; 2017. 
4. M9 Biopharmaceutics Classfication System-based Biowaivers. International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2019. 
5. Amidon GL, Lennernas H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic 
Drug Classification - the Correlation of in-Vitro Drug Product Dissolution and in-Vivo 
Bioavailability. Pharmaceut Res 1995; 12(3): 413-20. 
6. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic 
drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. 
Pharm Res 1995; 12(3): 413-20. 
7. Cannon WB. The movements of the stomach studied by means of the rontgen rays. Am J 
Physiol 1898; 1: 359-82. 
8. Johnson LR. Physiology of the gastrointestinal tract. 5th ed. London: Academic Press,; 
2012. p. 1 online resource (2 volumes). 
9. Ehrlein HJ, Schemann M. The Moving Gut by Hans Jörg Ehrlein and Michael Schemann. 
http://humanbiology.wzw.tum.de/index.php?id=22&L=1. 
10. Barrett KE. Gastrointestinal physiology.  McGraw-Hill's AccessMedicine. 2nd ed. New 
York, N.Y.: McGraw-Hill Education LLC,; 2014. p. xii, 321 p. 
11. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. 
Gastroenterology 2008; 134(7): 1842-60. 
12. Soybel DI. Anatomy and physiology of the stomach. Surg Clin North Am 2005; 85(5): 875-
94, v. 
13. Richardson CT, Feldman M. Effects of transdermal scopolamine, alone or in combination 
with cimetidine, on total 24 hour gastric acid secretion in patients with duodenal ulcer. Gut 1986; 
27(12): 1493-7. 
14. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in 
vitro testing. Mol Pharm 2010; 7(5): 1388-405. 
15. Doherty GM. Current Diagnosis & Treatment: Surgery. New York: McGraw-Hill; 2014. 
16. Gallagher N. Anatomy & Physiology II. 2013. 
http://anatomyphysiology2.weebly.com/digestive-system.html. 
17. . https://www.britannica.com/science/small-intestine. 
18. Schuster MM, Crowell MD, Koch KL. Schuster atlas of gastrointestinal motility in health 
and disease. 2nd ed. Hamilton: B.C. Decker; 2002. 
 87 
19. Schuster MM, Crowell MD, Koch KL. Schuster Atlas of Gastrointestinal Motility in Health 
and Disease. 2 ed. London: BC Decker Inc; 2002. 
20. Layer P, Goebell H. [Interdigestive motility and secretion of the gastrointestinal tract]. Z 
Gastroenterol 1987; 25(12): 769-76. 
21. Jodal M, Eklund S, Sjovall H. Enteric nerves and function of intestinal mucosa. 
Physiological and pathophysiological aspects. Dig Dis 1988; 6(4): 203-15. 
22. Sjovall H. Meaningful or redundant complexity - mechanisms behind cyclic changes in 
gastroduodenal pH in the fasting state. Acta Physiol (Oxf) 2011; 201(1): 127-31. 
23. Layer P, Chan AT, Go VL, DiMagno EP. Human pancreatic secretion during phase II 
antral motility of the interdigestive cycle. Am J Physiol 1988; 254(2 Pt 1): G249-53. 
24. Traynor OJ, Dozois RR, DiMagno EP. Canine interdigestive and postprandial gallbladder 
motility and emptying. Am J Physiol 1984; 246(4 Pt 1): G426-32. 
25. DiMagno EP. Regulation of interdigestive gastrointestinal motility and secretion. 
Digestion 1997; 58 Suppl 1: 53-5. 
26. Steingoetter A, Fox M, Treier R, et al. Effects of posture on the physiology of gastric 
emptying: a magnetic resonance imaging study. Scand J Gastroenterol 2006; 41(10): 1155-64. 
27. Ramsbottom N, Knox MT, Hunt JN. Gastric-Emptying of Barium-Sulfate Suspension 
Compared with That of Water. Gut 1977; 18(7): 541-2. 
28. Umenai T, Arai N, Chihara E. Effect of the preliminary hydration on gastric emptying time 
for water in healthy volunteers. Acta Anaesthesiol Scand 2009; 53(2): 223-6. 
29. Wright J, Adams V, Hykin J, et al. The measurement of gastric motor function and transit 
in man by echo planar magnetic resonance imaging. Magn Reson Mater Phy 1994; 2(3): 467-9. 
30. Oberle RL, Chen TS, Lloyd C, et al. The influence of the interdigestive migrating 
myoelectric complex on the gastric emptying of liquids. Gastroenterology 1990; 99(5): 1275-82. 
31. Mudie DM, Murray K, Hoad CL, et al. Quantification of gastrointestinal liquid volumes 
and distribution following a 240 mL dose of water in the fasted state. Mol Pharm 2014; 11(9): 
3039-47. 
32. Paixao P, Bermejo M, Hens B, et al. Gastric emptying and intestinal appearance of 
nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment 
stomach approach. Eur J Pharm Biopharm 2018; 129: 162-74. 
33. Schiller C, Frohlich CP, Giessmann T, et al. Intestinal fluid volumes and transit of dosage 
forms as assessed by magnetic resonance imaging. Aliment Pharm Therap 2005; 22(10): 971-9. 
34. Koziolek M, Alcaro S, Augustijns P, et al. The mechanisms of pharmacokinetic food-drug 
interactions - A perspective from the UNGAP group. European Journal of Pharmaceutical 
Sciences 2019; 134: 31-59. 
35. Ouyang A, Sunshine AG, Reynolds JC. Caloric Content of a Meal Affects Duration but 
Not Contractile Pattern of Duodenal Motility in Man. Digest Dis Sci 1989; 34(4): 528-36. 
36. Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Food and Drug 
Administration; 2018. 
37. Abuhelwa AY, Foster DJR, Upton RN. A Quantitative Review and Meta-models of the 
Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time. 
Aaps Journal 2016; 18(5): 1322-33. 
38. Jiang Y, Milavetz G, James MO, An GH. A Mechanism-Based Pharmacokinetic Enzyme 
Turnover Model for Dichloroacetic Acid Autoinhibition in Rats. J Pharm Sci-Us 2017; 106(5): 
1396-404. 
 88 
39. Cosson VF, Fuseau E. Mixed effect modeling of sumatriptan pharmacokinetics during drug 
development: II. From healthy subjects to phase 2 dose ranging in patients. J Pharmacokinet Biop 
1999; 27(2): 149-71. 
40. Rietbrock S, Merz PG, Fuhr U, et al. Absorption Behavior of Sulpiride Described Using 
Weibull Functions. Int J Clin Pharm Th 1995; 33(5): 299-303. 
41. Locatelli I, Mrhar A, Bogataj M. Gastric Emptying of Pellets under Fasting Conditions: A 
Mathematical Model. Pharmaceut Res 2009; 26(7): 1607-17. 
42. Siegel JA, Urbain JL, Adler LP, et al. Biphasic Nature of Gastric-Emptying. Gut 1988; 
29(1): 85-9. 
43. Wu K, Cohen EE, House LK, et al. Nonlinear population pharmacokinetics of sirolimus in 
patients with advanced cancer. CPT Pharmacometrics Syst Pharmacol 2012; 1: e17. 
44. Higaki K, Yamashita S, Amidon GL. Time-dependent oral absorption models. J 
Pharmacokinet Pharmacodyn 2001; 28(2): 109-28. 
45. Csajka C, Drover D, Verotta D. The use of a sum of inverse Gaussian functions to describe 
the absorption profile of drugs exhibiting complex absorption. Pharmaceut Res 2005; 22(8): 1227-
35. 
46. Stubbs DF. Models of gastric emptying. Gut 1977; 18(3): 202-7. 
47. Dressman JB, Fleisher D, Amidon GL. Physicochemical model for dose-dependent drug 
absorption. J Pharm Sci 1984; 73(9): 1274-9. 
48. Luner PE, Amidon GL. Description and simulation of a multiple mixing tank model to 
predict the effect of bile sequestrants on bile salt excretion. J Pharm Sci 1993; 82(3): 311-8. 
49. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral 
drug absorption. Int J Pharmaceut 1999; 186(2): 119-25. 
50. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and 
biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 Suppl 1: S41-
67. 
51. Langguth P, Lee KM, Spahn-Langguth H, Amidon GL. Variable gastric emptying and 
discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption 
on motility phase and pH. Biopharm Drug Dispos 1994; 15(9): 719-46. 
52. Talattof A, Price JC, Amidon GL. Gastrointestinal Motility Variation and Implications for 
Plasma Level Variation: Oral Drug Products. Mol Pharm 2016; 13(2): 557-67. 
53. Karatza E, Karalis V. Investigating the Impact of Gastric Emptying on Pharmacokinetic 
Parameters Using Delay Differential Equations and Principal Component Analysis. Eur J Drug 
Metab Ph 2021. 
54. Henin E, Bergstrand M, Weitschies W, Karlsson MO. Meta-analysis of Magnetic Marker 
Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the 
Gastrointestinal Tract Under Fed and Fasting Conditions. Pharmaceut Res 2016; 33(3): 751-62. 
55. Yokrattanasak J, De Gaetano A, Panunzi S, Satiracoo P, Lawton WM, Lenbury Y. A 
Simple, Realistic Stochastic Model of Gastric Emptying. PLoS One 2016; 11(4): e0153297. 
56. Talattof A, Amidon GL. Pulse Packet Stochastic Model for Gastric Emptying in the Fasted 
State: A Physiological Approach. Mol Pharmaceut 2018; 15(6): 2107-15. 
57. Hens B, Tsume Y, Bermejo M, et al. Low Buffer Capacity and Alternating Motility along 
the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of 
Ionizable Drugs. Mol Pharm 2017. 
 89 
58. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. 
Characterization of the human upper gastrointestinal contents under conditions simulating 
bioavailability/bioequivalence studies. Pharmaceut Res 2006; 23(1): 165-76. 
59. Clarysse S, Tack J, Lammert F, Duchateau G, Reppas C, Augustijns P. Postprandial 
evolution in composition and characteristics of human duodenal fluids in different nutritional 
states. J Pharm Sci 2009; 98(3): 1177-92. 
60. Kaunitz JD, Akiba Y. Review article: duodenal bicarbonate - mucosal protection, luminal 
chemosensing and acid-base balance. Aliment Pharmacol Ther 2006; 24 Suppl 4: 169-76. 
61. Hogan DL, Ainsworth MA, Isenberg JI. Review article: gastroduodenal bicarbonate 
secretion. Aliment Pharmacol Ther 1994; 8(5): 475-88. 
62. Fuchs A, Dressman JB. Composition and physicochemical properties of fasted-state human 
duodenal and jejunal fluid: a critical evaluation of the available data. J Pharm Sci 2014; 103(11): 
3398-411. 
63. McNamara DP, Whitney KM, Goss SL. Use of a physiologic bicarbonate buffer system 
for dissolution characterization of ionizable drugs. Pharmaceut Res 2003; 20(10): 1641-6. 
64. Koenigsknecht MJ, Baker JR, Wen B, et al. In Vivo Dissolution and Systemic Absorption 
of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted 
Conditions. Mol Pharmaceut 2017; 14(12): 4295-304. 
65. Cheng LS, Wong H. Food Effects on Oral Drug Absorption: Application of 
Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool. Pharmaceutics 2020; 
12(7). 
66. Abuhelwa AY, Foster DJR, Upton RN. A Quantitative Review and Meta-Models of the 
Variability and Factors Affecting Oral Drug Absorption-Part I: Gastrointestinal pH. Aaps Journal 
2016; 18(5): 1309-21. 
67. Drugs@FDA. Silver Spring, MD: U.S. Food and Drug Administration. 
68. CellCept (mycophenolate mofetil) [package insert]. San Francisco, CA; F. Hoffmann-La 
Roche AG; 1995. 
69. Armstrong VW, Tenderich G, Shipkova M, et al. Pharmacokinetics and bioavailability of 
mycophenolic acid after intravenous administration and oral administration of mycophenolate 
mofetil to heart transplant recipients. Ther Drug Monit 2005; 27(3): 315-21. 
70. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of 
mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. 
Journal of Clinical Pharmacology 1996; 36(4): 315-24. 
71. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate 
in solid organ transplant recipients. Clin Pharmacokinet 2007; 46(1): 13-58. 
72. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation - 
Physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41(10): 751-
90. 
73. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of 
mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26(6): 600-8. 
74. Naesens M, Kuypers DRJ, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 
genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. 
Transplantation 2006; 82(8): 1074-84. 
75. Blume HH, Midha KK. Bio-International-92, Conference on Bioavailability, 
Bioequivalence, and Pharmacokinetic Studies. J Pharm Sci-Us 1993; 82(11): 1186-9. 
 90 
76. Shah VP, Yacobi A, Barr WH, et al. Evaluation of orally administered highly variable 
drugs and drug formulations. Pharmaceut Res 1996; 13(11): 1590-4. 
77. Westlake WJ. Bioequivalence Testing - a Need to Rethink - Reply. Biometrics 1981; 37(3): 
591-3. 
78. Schuirmann DJ. A Comparison of the 2 One-Sided Tests Procedure and the Power 
Approach for Assessing the Equivalence of Average Bioavailability. J Pharmacokinet Biop 1987; 
15(6): 657-80. 
79. Davit BM, Chen ML, Conner DP, et al. Implementation of a reference-scaled average 
bioequivalence approach for highly variable generic drug products by the US Food and Drug 
Administration. AAPS J 2012; 14(4): 915-24. 
80. Patel S, Chauhan V, Mandal J, et al. Single-dose, Two-way Crossover, Bioequivalence 
Study of Mycophenolate Mofetil 500 mg Tablet Under Fasting Conditions in Healthy Male 
Subjects. Clinical Therapeutics 2011; 33(3): 378-90. 
81. Almeida S, Filipe A, Neves R, et al. Mycophenolate Mofetil 500-mg Tablet Under Fasting 
Conditions: Single-Dose, Randomized-Sequence, Open-Label, Four-Way Replicate Crossover, 
Bioequivalence Study in Healthy Subjects. Clinical Therapeutics 2010; 32(3): 556-74. 
82. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. 
Journal of Pharmacy and Pharmacology 1999; 51(10): 1143-8. 
83. Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in 
kidney transplant pediatric and adolescent patients. Ther Drug Monit 2005; 27(3): 378-88. 
84. Cremers S, Schoemaker R, Scholten E, et al. Characterizing the role of enterohepatic 
recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal 
transplant patients by pharmacokinetic modelling. Brit J Clin Pharmaco 2005; 60(3): 249-56. 
85. Jiao Z, Ding JJ, Shen J, et al. Population pharmacokinetic modelling for enterohepatic 
circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in 
UGT1A9. Brit J Clin Pharmaco 2008; 65(6): 893-907. 
86. Yau WP, Vathsala A, Lou HX, Zhou SF, Chan E. Mechanism-Based Enterohepatic 
Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact 
of Cyclosporine Dose in Asian Renal Transplant Patients. Journal of Clinical Pharmacology 2009; 
49(6): 684-99. 
87. Sam WJ, Akhlaghi F, Rosenbaum SE. Population Pharmacokinetics of Mycophenolic Acid 
and Its 2 Glucuronidated Metabolites in Kidney Transplant Recipients. Journal of Clinical 
Pharmacology 2009; 49(2): 185-95. 
88. de Winter BCM, Neumann I, van Hest RM, van Gelder T, Mathot RAA. Limited Sampling 
Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With 
Autoimmune Disease. Ther Drug Monit 2009; 31(3): 382-90. 
89. Lennernas H. Human intestinal permeability. J Pharm Sci-Us 1998; 87(4): 403-10. 
90. Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical 
design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliver Rev 
1996; 19(3): 359-76. 
91. Scheubel E, Adamy L, Cardot JM. Mycophenolate Mofetil: Use of a Simple Dissolution 
Technique to Assess Generic Formulation Differences. Dissolut Technol 2012; 19(1): 52-8. 
92. Bermejo M, Paixao P, Hens B, et al. Linking the Gastrointestinal Behavior of Ibuprofen 
with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions. Mol 
Pharmaceut 2018; 15(12): 5454-67. 
 91 
93. Tsume Y, Langguth P, Garcia-Arieta A, Amidon GL. In silico prediction of drug 
dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: 
ibuprofen and ketoprofen. Biopharmaceutics & Drug Disposition 2012; 33(7): 366-77. 
94. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions 
in the proximal human gastrointestinal tract: An update. Pharmaceut Res 2008; 25(7): 1663-76. 
95. The United States Phamacopedia USP 31. Rockville: The United States Pharmacopedial 
Convention Inc; 2008. 
96. Sherwin CMT, Fukuda T, Brunner HI, Goebel J, Vinks AA. The Evolution of Population 
Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid 
Organ Transplantation and Autoimmune Disease. Clin Pharmacokinet 2011; 50(1): 1-24. 
97. Pustejovsky J, Stubbs A. Natural Language Annotation for Machine Learning. 1 ed. 1005 
Gravenstein Highway North, Sebastopol, CA 95472: O’Reilly Media, Inc.; 2012. 
98. Reed J. NATURAL LANGUAGE PROCESSING – How Life Sciences Companies Are 
Leveraging NLP From Molecule to Market. 2020. https://drug-dev.com/natural-language-
processing-how-life-sciences-companies-are-leveraging-nlp-from-molecule-to-market/. 
99. Kristensen NR, Madsen H, Jorgensen SB. Parameter estimation in stochastic grey-box 
models. Automatica 2004; 40(2): 225-37. 
 
